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The activity of voltage-gated sodium channels has long been linked to disorders of neuronal excitability such as epilepsy and
chronic pain. Recent genetic studies have now expanded the role of sodium channels in health and disease, to include autism,
migraine, multiple sclerosis, cancer as well as muscle and immune system disorders. Transgenic mouse models have proved
useful in understanding the physiological role of individual sodium channels, and there has been significant progress in the
development of subtype selective inhibitors of sodium channels. This review will outline the functions and roles of specific
sodium channels in electrical signalling and disease, focusing on neurological aspects. We also discuss recent advances in the
development of selective sodium channel inhibitors.
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Abbreviations: TTX = tetrodotoxin; VGSC = voltage-gated sodium channel
Sodium channels
Structure and activity
The voltage-gated sodium channel (VGSC) gene family comprises
nine homologous members SCN1A to SCN11A, which encode the
sodium selective ion channels NaV1.1 to NaV1.9. Nax (SCN6A/
SCN7A), though structurally related to VGSCs, is not activated by
membrane depolarization, but rather by altered sodium
concentrations (Goldin et al., 2000). Each large -subunit
(260 kDa) contains four homologous domains DI–DIV, with each
domain containing six transmembrane segments. One -subunit
alone is necessary and sufficient to form a functional channel; how-
ever -subunits also associate with b-subunits (SCN1B to SCN4B),
which modulate channel biophysics and trafficking. At resting mem-
brane potentials, VGSCs are closed, requiring depolarization to be
activated. Upon activation they contribute to the upstroke of the
action potential in excitable cells (Fig. 1A and B). Channel opening
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Figure 1 Gating model and contribution of voltage-gated sodium channels to neuronal and cardiac action potential firing. Upper traces
depict a cartoon representation of a whole-cell current clamp recording from a typical neuron (A) or cardiac myocyte (B). Dotted line
indicates the resting membrane potential (Vm). Lower trace is temporally aligned to the upper trace and shows the change in sodium
current (INa) during an action potential. Note a downward deflection of the trace reflects an inward movement of sodium ions into the cell.
(1) At the resting membrane potential VGSCs are closed. A small depolarization of the neuronal membrane potential in response to
sensory input or receptor input depolarizes the neuronal membrane potential to the threshold for VGSC activation (50 mV). (2) VGSCs
activate rapidly (1 ms to peak) allowing the influx of sodium and depolarizing the membrane potential further, forming the upstroke of
the action potential. Note that the peak sodium current correlates with the peak of the action potential. (3) Following activation the
sodium channels inactivate resulting in a decrease in sodium current and repolarization of the neuronal membrane potential, contributing
to the downstroke of the action potential. Recovery from inactivation allows the channels to participate in the next action potential. (C)
Mechanism of voltage sensitive gating of VGSCs. The left channel represents a VGSC in a deactivated (closed) state. A small depolarization
of the membrane potential causes a movement of the positively charged S4 voltage-sensor domain (green) leading to a conformational
change in the protein and opening of the pore (middle channel). Following activation, the pore is rapidly occluded by the inactivation gate,
resulting in inactivation of the sodium channel (right channel).
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results in a rapid influx of sodium ions into the cell and further
depolarization of the membrane potential towards the equilibrium
potential for sodium (+ 60 mV in most neurons). VGSCs close
within milliseconds of opening, a process called fast inactivation
that contributes to the downstroke of the action potential
(Fig. 1C). In many neurons, inactivation of VGSCs is incomplete,
resulting in a small persistent Na+ current, which inactivates over a
time period of tens of seconds. Functionally, the structure of the
VGSCs can be divided into two parts with the transmembrane do-
mains S1–S4 contributing to the voltage sensor and S5–S6 arranging
to form the sodium selective pore (Stuhmer et al., 1989; Catterall
et al., 2005). The molecular mechanism by which changes in mem-
brane voltage confer a conformational change on voltage-gated ion
channel proteins is through the movement of modular voltage sen-
sors contained within the S4 segment of domains I–IV (Fig. 1C)
(Alabi et al., 2007). The voltage sensors contain repeated motifs
of positively charged amino acids followed by hydrophobic residues
arranged in an -helix with a linear array of positively charged
residues. Depolarization of the cell alters the electric field across
the cell membrane resulting in the rapid movement of the DI–III
S4 voltage sensors and a conformational change in the protein
which opens the ion channel pore. Inactivation follows activation
due to the intrinsically slower movement of the DIV voltage sensor
(Bosmans et al., 2008). The VGSC inactivation gate contains a trio
of amino acids (IFM) located in a highly conserved intracellular loop
connecting domains III and IV (West et al., 1992). Upon inactiva-
tion, the inactivation gate moves into the channel pore as shown by
the altered accessibility of antibodies targeted to this domain
(Vassilev et al., 1988, 1989), resulting in occlusion of the pore
often depicted as a ball and chain type block (Fig. 1C). The channels
remain in a refractory inactivated state until the cell membrane
potential repolarizes, normally facilitated by the delayed activation
of voltage-gated potassium channels.
Much of what is known about the molecular mechanism of
voltage sensing derives from studies on voltage-gated potassium
channels for which high-resolution crystal structures have been
obtained. Using X-ray crystallography the structure of the S4 volt-
age sensor in the Archaea voltage-dependent potassium channel
KvAP was modelled as a paddle (Jiang et al., 2003a, b). However,
recent modelling of the bacterial sodium channel NaChBac reveals
that the S4 voltage sensor segment is arranged in a 3(10) alpha
helical conformation that slides in a linear fashion through a
narrow groove formed by the S1, S2 and S3 segments
(Yarov-Yarovoy et al., 2012). Recently, the crystal structure of a
VGSC has been reported (Payandeh et al., 2011). Comparison
with the previous open potassium channel structures showed
that the voltage-sensor domains and the S4–S5 linkers dilate the
central pore by pivoting together around a hinge at the base of
the pore module (Payandeh et al., 2011). This newly described
crystal structure of a prokaryotic VGSC shows that the basis of ion
channel selectivity for Na + is different from potassium channels
(Corry and Thomas, 2012).
Persistent sodium currents
All the kinetically fast transient channels (NaV1.1–1.7) appear
quite similar in functional properties, but sodium channels
sometimes generate much longer openings as a result of incom-
plete or defective fast inactivation. NaV1.9 gives rise to a low-
threshold, persistent tetrodotoxin (TTX)-resistant Na + current in
sensory neurons (Baker et al., 2003). Persistent sodium currents
have also been recorded in cells that do not express NaV1.9,
including cardiac and skeletal muscle (Patlak and Ortiz, 1986;
Bohle and Benndorf, 1995), large diameter dorsal root ganglion
neurons (Baker and Bostock, 1997) and cortical pyramidal neurons
(Alzheimer et al., 1993; Schwindt and Crill, 1995). In some
voltage-clamp protocols the amplitude of persistent current is
just a few per cent of that of the transient current at the same
potentials but is still functionally important. For mammalian pri-
mary sensory neurons, persistent currents activate at more nega-
tive potentials than the associated transient currents. The
hyperpolarized voltage dependence of activation of persistent
sodium currents allows these channels to operate as amplifiers of
subthreshold depolarization, because their activation kinetics are
fast and they operate over a strategic subthreshold membrane
potential range with low potassium channel activation. Evidence
from muscle fibre recordings indicates that NaV1.4 can generate
persistent currents, and NaV1.6 generates such currents in cere-
bellar Purkinje neurons (Raman et al., 1997; Raman and Bean,
1997). The functional importance of persistent currents can be
seen from the effects of SCN8A mutations that change neuron
firing patterns and lead to ataxia in mice (Meisler et al., 2002,
2004). In addition, many epileptogenic mutations of SNC1A,
SCN2A and SCN3A exhibit increased persistent currents (Meisler
and Kearney, 2005). The implication of these findings is that spe-
cific blocking of channels with inactivation-defective gating might
be a useful way of controlling membrane excitability within the
nervous system (Lampl et al., 1998). In primary sensory neurons,
persistent currents are preferentially targeted by local anaesthetics
(Baker, 2000). Local anaesthetics can suppress ectopic firing in
damaged sensory neurons without altering action potential prop-
erties (Devor et al., 1992), probably because the block of persist-
ent currents takes the membrane potential further away from
firing threshold.
Resurgent sodium currents
Resurgent currents, first observed in cerebellar Purkinje neurons
(Raman and Bean, 1997) and present in dorsal root ganglion neu-
rons (Cummins et al., 2005), may arise following relief of
ultra-fast open-channel block (faster than pore block by the in-
activation gate) mediated by yet undetermined proteins. In some
neurons, sodium channels transiently open upon recovery from
inactivation when the membrane potential is repolarized. This
transient opening gives rise to a large inward tail current termed
‘resurgent current’ (Cannon and Bean, 2010). One possible mech-
anism for resurgent current involves the blockade of the channel
pore by the C-terminus of b4 subunit of sodium channels (Grieco
et al., 2005; Bant and Raman, 2010). Resurgent currents have
recently become an important topic in pain and myopathy re-
search as sodium channel mutations involved in these pathologies
were found to increase resurgent currents (Jarecki et al., 2010).
Mutations in NaV1.4, NaV1.5 and NaV1.7 that lead to paramyo-
tonia congenita, cardiac long QT syndrome/sudden infant death
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syndrome and paroxysmal extreme pain disorder, respectively, all
enhance resurgent currents, thereby affecting the firing properties
of the cells. Although resurgent current can be observed with
NaV1.4-, NaV1.5-, NaV1.6- and NaV1.7-based sodium channels
in expression studies, in vivo resurgent currents have only been
recorded from neurons and never from cardiac or skeletal muscle.
Many toxins affect sodium channel function by altering the
gating of these channels. The wasp venom b-pompilidotoxin
(b-PMTX) is able to produce resurgent currents through a molecu-
lar mechanism involving the slowing of sodium channel inactiva-
tion (Grieco and Raman, 2004). Another toxin, the Cn2 b-scorpion
peptide, shifts the activation of NaV1.2 and NaV1.6 towards more
hyperpolarized potentials by trapping the DII S4 voltage sensor in
the inactivated rather than the closed state. A b-scorpion toxin
also has the capability of producing resurgent currents by trapping
the voltage sensor of human NaV1.6 channels and VGSC in mouse
Purkinje cells (Schiavon et al., 2006). The data from these two
studies strongly suggest that an increased open probability of
sodium channels is a key requirement for the generation of resur-
gent currents. Very recently it has been suggested that the tran-
sient, resurgent and persistent phases of the sodium current in
cerebellar granule cells are all interlinked through the b4 subunit
(Bant and Raman, 2010). These results highlight the critical role
that toxins play in unravelling gating mechanisms of sodium
channels.
Voltage-gated sodium channel
function and disease
association
The nine different VGSC -subunits are differentially expressed
(Table 1), and disruption of VGSC function can lead to a broad
range of pathologies. The role of VGSCs in epilepsy and pain has
been well established; however, there is increasing evidence of a
role for VGSCs in other disorders including cancer, multiple scler-
osis, muscle and immune disorders, autism, neurodegeneration
and cardiovascular complications (Table 1). Human heritable dis-
orders can now be mapped with relative ease. A number of dis-
orders have been ascribed to mutations in genes encoding sodium
channels and further genetic insights have been provided by ana-
lysis of targeted sodium channel mutations and gene deletion in
mice (Table 1). The correlation between the clinical phenotype of
patients with channel mutations and channel biophysical proper-
ties and observations in mouse models will be discussed later.
NaV1.1 (SCN1A)
Broadly expressed in the CNS, NaV1.1 expression may be prefer-
entially expressed in inhibitory gamma-aminobutyric acidergic
(GABAergic) neurons (Yu et al., 2006). The majority of the
4700 associated SCN1A mutations are nonsense causing the
autosomal dominant disorder Dravet’s syndrome. In addition, ap-
proximately two dozen SCN1A mutations have been identified in
families with the milder disorder, generalized epilepsy with febrile
seizures plus, which is characterized by short-lasting tonic–clonic
seizures accompanied by fever (Meisler et al., 2010). Generalized
epilepsy with febrile seizures plus mutations change expression
and function of NaV1.1 channels due to both gain- and loss-of-
function mutations. For example, the D188V mutation leads to
impaired slow inactivation (Cossette et al., 2003), while the
T875M mutation enhances slow inactivation (Spampanato et al.,
2001). Both mutations lead to the same phenotype. Thus, the
relationship between the clinical phenotypes and the functional
defects is complex (reviewed in Ragsdale, 2008). Some linkage
between specific genetic abnormalities and phenotype has been
shown; SCN1A mutations are associated with early onset of febrile
seizures/febrile seizures plus while SCN1B mutations are associated
with later onset (Sijben et al., 2009).
The more detrimental severe myoclonic epilepsy of infancy (or
Dravet’s syndrome) is associated with haploinsufficiency for
SCN1A in 50–80% of severe myoclonic epilepsy of infancy pa-
tients caused by more deleterious nonsense and frameshift muta-
tions in NaV1.1 (De Jonghe, 2011). In contrast to generalized
epilepsy with febrile seizures plus, these mutations prevent
channel expression or severely impair channel function. While
loss-of-function mutations are common in Dravet’s syndrome, a
gain-of-function mutation in SCN1A (R865G) has also been found
(Volkers et al., 2011). SCN1A duplications and deletions are also
found in patients with Dravet’s syndrome (Marini et al., 2009).
More recently, de novo SCN1A mutations have been found in
patients with the severe early infantile onset syndrome of malig-
nant migrating partial seizures, also a severe epileptic encephalop-
athy (Carranza et al., 2011).
The severity of channel impairment has been suggested to
underlie the different efficacies of some anti-epileptic drugs in
treating either generalized epilepsy with febrile seizures plus or
severe myoclonic epilepsy of infancy, of which many act through
inhibiting VGSCs. For example, the sodium channel blocker lamo-
trigine is very effective for treating generalized epilepsy with fe-
brile seizures plus, while it aggravates symptoms in patients with
severe myoclonic epilepsy of infancy (Guerrini et al., 1998). The
efficacy of some frontline anti-epileptic drugs, which often work
through stabilizing channels in the inactive state, has been sug-
gested to be influenced by a polymorphism that modifies splicing
of NaV1.1 leading to altered inactivation (Fletcher et al., 2011).
Studies on Scn1a+ / mice have shown that deletion of NaV1.1
leads to impaired firing of GABAergic inhibitory hippocampal inter-
neurons (Catterall and Kalume, 2010) and cerebellar GABAergic
Purkinje neurons (Kalume et al., 2007). The impaired functioning
of inhibitory GABAergic neurons may contribute to seizures,
ataxia, spasticity and failure of motor coordination observed in
these mice.
It is interesting to note that targeting NaV1.1 to treat epilepsy is
not the only possible therapeutic strategy. Mice with haploinsuffi-
ciency for both NaV1.1 and NaV1.6 showed reduced susceptibility
to drug-induced seizures compared with NaV1.1 heterozygotes
(Martin et al., 2007). In contrast with NaV1.1, NaV1.6 is highly
expressed in excitatory neurons (Caldwell et al., 2000). Thus it
seems that the excitatory and inhibitory balance in the brain is
restored by NaV1.6 mutations that reduce firing of excitatory neu-
rons. Finally, NaV1.1 mutations are also associated with familial
hemiplegic migraine type 3 (Dichgans et al., 2005), an autosomal
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dominant severe subtype of migraine with aura characterized by
hemiparesis during the attacks. Genome-wide linkage analysis re-
vealed three families with the same missense mutation in SCN1A
(Q1489K). This mutation resulted in complex changes in channel
gating including a depolarizing shift in the voltage dependence of
inactivation, accelerated recovery from inactivation and increased
persistent current (Cestele et al., 2008). These biophysical changes
could cause either hyper- or hypoexcitability depending on the
firing frequency and resting membrane potential of the neuron.
More recently, whole exome sequencing has identified candidate
genes with de novo mutations, including SCN1A, in sporadic
autism spectrum disorders (O’Roak et al., 2011, 2012).
NaV1.2 (SCN2A)
NaV1.2 is abundantly expressed in the adult CNS, particularly in
the cortex and hippocampus (Westenbroek et al., 1989), where it
is primarily expressed in unmyelinated axons and dendrites (Boiko
et al., 2001). Early in development, NaV1.2 is highly expressed in
regions destined to become nodes of Ranvier and is replaced
during development by NaV1.6 (Boiko et al., 2001; Kaplan
et al., 2001). NaV1.2 knockout mice die perinatally from neuronal
apoptosis and hypoxia (Planells-Cases et al., 2000). In humans,
NaV1.2 mutations are associated with inherited epilepsy, mainly
benign familial neonatal-infantile seizures (Heron et al., 2002)
and less frequently with other forms of epilepsy such as general-
ized epilepsy with febrile seizures plus (Sugawara et al., 2001).
Benign familial neonatal-infantile seizure is an autosomal dominant
disorder characterized by afebrile seizures with onset within
4 months after birth and spontaneous remission within the first
year of life, without residual neurological deficits. Three separate
benign familial neonatal-infantile seizures causing mutations in
NaV1.2 resulted in reduced plasma membrane expression while
having varied effects on channel activation and inactivation
(Misra et al., 2008). Although there is little consensus over the
pathological mechanisms, studies have demonstrated that either
gain- or loss-of-function mutations of NaV1.2 are associated
with disease. A link between NaV1.2 and autism has been re-
ported at low frequency (1/229 autism families studied), resulting
in mutation of the calmodulin binding domain of NaV1.2 and
reduced calmodulin-binding affinity (Weiss et al., 2003).
De novo mutations revealed by whole-exome sequencing includ-
ing two independent nonsense mutations in SCN2A, are strongly
associated with autism (Sanders et al., 2012).
NaV1.3 (SCN3A)
NaV1.3 is widely expressed in the human brain and has a predom-
inantly somatodendritic expression pattern (Whitaker et al., 2001).
In contrast to many of the other VGSC genes, there are as yet no
clear monogenic diseases associated with SCN3A mutation.
However, a small study of patients with cryptogenic paediatric
partial epilepsy revealed a mutation in SCN3A (K354Q) that led
to an increase in persistent current and induced epileptiform
hyperexcitability in hippocampal neurons (Holland et al., 2008a;
Estacion et al., 2010). Animal studies have focused on a possible
role of NaV1.3 in neuropathic pain. Following axotomy and
inflammation in mice, NaV1.3 transcript levels increase in sensory
neurons (Waxman et al., 1994b; Dib-Hajj et al., 1999). Antisense
knockdown of NaV1.3 expression attenuates pain-related behav-
iour associated with spinal cord injury and chronic constriction
injury (Hains et al., 2004) but not allodynia in the spared nerve
injury model (Lindia et al., 2005). However, NaV1.3 knockout
mice, where the gene was deleted globally or selectively in noci-
ceptive neurons, showed normal pain behaviour and normal de-
velopment of neuropathic pain in the Chung model of neuropathic
pain (Nassar et al., 2006). Although several lines of investigation
have implicated NaV1.3 as a candidate drug target to treat neuro-
pathic pain, this study does not support an essential role for
NaV1.3 in neuropathic pain.
NaV1.4 (SCN4A)
NaV1.4 is responsible for the generation and propagation of action
potentials that initiate muscle contraction. Currently, five heredi-
tary sodium channelopathies of skeletal muscle involving NaV1.4
mutations have been identified, such as hyperkalaemic periodic
paralysis, hypokalaemic periodic paralysis, paramyotonia conge-
nita, potassium-aggravated myotonia and congenital myasthenic
syndrome (Jurkat-Rott et al., 2010). Hypokalaemic periodic par-
alysis and normokalaemic peridodic paralysis causing mutations
map to the NaV1.4 voltage sensor, resulting in ionic leak through
the gating pore allowing sustained inward sodium flux at negative
membrane potentials (Sokolov et al., 2010). In contrast, mutations
associated with paramyotonia congenita and hyperkalaemic peri-
odic paralysis are widespread in the NaV1.4 protein and either
enhance activation or impair inactivation resulting in hyperexcit-
ability. Mutations in KCNA1 and SCN4A have been found in a
patient with episodic ataxia and paramyotonia congenita. Coex-
istence of these two ion channelopathies in this patient raises the
possibility of a role of sodium channels in episodic ataxias (Raja-
kulendran et al., 2009).
NaV1.5 (SCN5A)
Several syndromes leading to sudden cardiac death have been
linked to NaV1.5. For example, over 80 SCN5A mutations have
been identified in patients with long QT syndrome type 3 (Zimmer
and Surber, 2008). These mutations mostly disrupt fast inactiva-
tion, thereby causing persistent sodium currents (Bennett et al.,
1995). Similarly, Brugada syndrome also leads to sudden cardiac
death that may account for up to 50% of all sudden cardiac
deaths in young individuals without structural heart disease.
SCN5A mutations were found in 20% of patients with
Brugada syndrome (Kapplinger et al., 2010) resulting in channel
loss-of-function through a number of different mechanisms includ-
ing expression of non-functional NaV1.5 (Valdivia et al., 2004;
Hsueh et al., 2009), decreased protein expression (Kyndt et al.,
2001), impaired membrane trafficking (Baroudi et al., 2001, 2002)
or defective channel inactivation (Hsueh et al., 2009). Although
NaV1.5 has been mainly linked to cardiac disease, a more recent
report shows a novel SCN5A mutation in a patient with idiopathic
epilepsy who died in sudden unexpected death in epilepsy
(SUDEP) (Aurlien et al., 2009)
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Interestingly, VGSC upregulation has been associated with sev-
eral strongly metastatic carcinomas, leading to the hypothesis that
VGSC upregulation may ‘switch’ the cancerous cell to a highly
invasive state (Onkal and Djamgoz, 2009). Some cancers express
embryonic/neonatal VGSC splice variants, for example, a neonatal
isoform of NaV1.5 (seven amino acid differences) is the predom-
inant (480%) VGSC in human metastatic breast cancer (Fraser
et al., 2005) as well as neuroblastoma (Ou et al., 2005).
NaV1.6 (SCN8A)
NaV1.6 is broadly expressed in the nervous system in a variety of
cells including Purkinje cells, motor neurons, pyramidal and gran-
ule neurons, glial cells and Schwann cells and is enriched at the
nodes of Ranvier (Caldwell et al., 2000; Kearney et al., 2002).
Mutation in SCN8A is not a common cause of human disease
although a patient with a heterozygous mutation in SCN8A has
been described with mental retardation, pancerebellar atrophy and
ataxia (Trudeau et al., 2006). This mutation caused a C-terminal
truncation of NaV1.6 resulting in predicted loss of channel func-
tion. Naturally occurring med mutant NaV1.6 knockout mice show
a range of movement disorders including tremor, ataxia, dystonia
and paralysis (Meisler et al., 2002, 2004). Mutant mice are also
reported to have disordered sleep patterns with a chronic impair-
ment of REM sleep and enhanced spatial memory (Papale et al.,
2010). In Purkinje cells of NaV1.6 knockout mice, resurgent cur-
rents are reduced and spontaneous and evoked firing was attenu-
ated (Raman et al., 1997). Recently a de novo pathogenic SCN8A
mutation with greatly increased persistent current was identified in
a case of SUDEP with infantile epileptic encephalopathy
(Veeramah et al., 2012). Persistent NaV1.6 activity can trigger
axonal injury within white matter axons during experimental auto-
immune encephalomyelitis, an animal model of multiple sclerosis
(Craner et al., 2004). In non-excitable cells such as macrophages,
NaV1.6 is expressed at an intracellular location on podosomes
(Carrithers et al., 2009a). In this study, inhibition of NaV1.6 with
TTX or by genetic ablation was effective at reducing invasion of
macrophages into melanoma. Similarly, a non-neuronal role for
NaV1.6 contributing to the invasiveness of cervical carcinomas
has been suggested (Hernandez-Plata et al., 2012). This suggests
that targeting NaV1.6 in non-neuronal tissue might have thera-
peutic potential to treat cancer or autoimmune disorders such as
multiple sclerosis (Carrithers et al., 2009b). However, the essential
role of NaV1.6 in many neurological functions may make this a
difficult task.
NaV1.7 (SCN9A)
NaV1.7 is expressed in peripheral sensory neurons innervating the
skin, viscera and orofacial region (dorsal root and trigeminal gang-
lia) as well as sympathetic neurons and olfactory epithelia
(Toledo-Aral et al., 1997; Weiss et al., 2011). A number of
human heritable pain disorders map to mutations in SCN9A, the
gene encoding NaV1.7 (Dib-Hajj et al., 2010). Dominant gain-of-
function mutations lead to inherited primary erythromelalgia,
which is characterized by bilateral burning pain of the feet/lower
legs and hands, elevated skin temperature of affected areas and
reddened extremities (Yang et al., 2004). Additionally, dominant
gain-of-function mutations can cause paroxysmal extreme pain
disorder which is characterized by episodic burning pain of the
rectum, ocular and mandibular regions (Fertleman et al., 2006).
Rare recessive loss-of-function conditions can cause an inability to
experience pain (Cox et al., 2006; Ahmad et al., 2007) and an-
osmia (Weiss et al., 2011).
Biophysical characterization of the NaV1.7 mutations present in
patients with erythromelalgia shows a significant hyperpolarizing
shift in voltage dependence of activation (Cummins et al., 2007),
resulting in gain-of-function. The NaV1.7 mutations underlying
paroxysmal extreme pain disorder, where mechanical stimulation
evokes excruciating pain (Fertleman et al., 2006), attenuate the
fast inactivation of NaV1.7 resulting in persistent sodium currents.
Such a deficit in inactivation is predicted to produce prolonged
bursts of action potentials leading to increased nociceptive signal-
ling. In mouse studies, selective knockout of NaV1.7 expression in
NaV1.8-positive nociceptors lead to a loss of acute noxious
mechanosensation and inflammatory pain (Nassar et al., 2004),
while deletion of NaV1.7 in all sensory neurons leads to additional
loss of noxious thermosensation (Minett et al., 2012). These data
suggest that NaV1.7 expressed within NaV1.8-positive sensory
neurons are important for acute noxious mechanosensation,
whilst NaV1.7 expressed within NaV1.8 negative dorsal root gan-
glion neurons are essential for acute noxious thermosensation.
Furthermore, no effect on neuropathic pain behaviour was
observed in mice that lack expression of NaV1.7 in NaV1.8-positive
sensory neurons (Nassar et al., 2005). This is also true for mice in
which NaV1.7 has been deleted from all dorsal root ganglion neu-
rons. In contrast, mice in which NaV1.7 is deleted from all sensory
neurons as well as sympathetic neurons show a dramatic reduction
in mechanical hypersensitivity following a surgical model of neuro-
pathic pain, demonstrating an important role for NaV1.7 in sym-
pathetic neurons in the development of neuropathic pain (Minett
et al., 2012). Overall, the role of NaV1.7 in human as well as
animal pain perception highlights NaV1.7 as an important anal-
gesic drug target.
NaV1.7 is not only implicated in pain perception. Weiss et al.
(2011) demonstrated that NaV1.7 is an essential requirement for
odour perception in both mice and humans. Surprisingly, NaV1.7 is
required for synaptic signalling from the primary olfactory neurons
to mitral cells, and the release of substance P from nociceptive
neurons has also been shown to be NaV1.7-dependent (Weiss
et al., 2011; Minett et al., 2012).
NaV1.8 (SCN10A)
NaV1.8 is a TTX-resistant sodium channel subtype that is ex-
pressed in nociceptive sensory neurons (Akopian et al., 1999)
and acts as a major contributor to the upstroke of action potentials
(Renganathan et al., 2001). NaV1.8 is essential in maintaining the
excitability of nociceptors at low temperatures (Zimmermann
et al., 2007), becoming the sole electrical impulse generator at
temperatures 510C. This is caused by enhanced slow inactiva-
tion of TTX-sensitive channels in response to cooling, whereas
inactivation of NaV1.8 is cold resistant. Behavioural studies of
mice in which NaV1.8 expressing sensory neurons are ablated
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show loss of response to noxious cold and noxious mechanical
stimuli (Abrahamsen et al., 2008). Antisense studies have shown
an important role for NaV1.8 channels in inflammatory pain
(Khasar et al., 1998). Antisense oligonucleotides attenuate the
development and maintenance of neuropathic pain in rats (Lai
et al., 2002; Joshi et al., 2006) while small interfering RNA select-
ive knockdown of NaV1.8 reverses mechanical allodynia (Dong
et al., 2007). However, NaV1.8 knockout mice as well as
NaV1.7/1.8 double knockout mice show normal neuropathic
pain behaviour (Kerr et al., 2001; Nassar et al., 2005).
However, selective blockers of NaV1.8 such as A-803467 (Jarvis
et al., 2007) and ambroxol (Gaida et al., 2005) successfully
suppress various pain symptoms and neuropathic pain in rats.
A recent genome wide association study has identified a single
nucleotide polymorphism in NaV1.8 which was associated
with prolonged cardiac conduction (Chambers et al., 2010)
(longer P-wave duration, PR interval and QRS duration), thereby
providing evidence that NaV1.8 has a functional role in the heart,
probably through effects on innervation rather than cardiac
muscle.
NaV1.9 (SCN11A)
NaV1.9 is the most recently discovered VGSC subtype (Dib-Hajj
et al., 1998). It is a marker of primary nociceptors (Fang et al.,
2002) and is also expressed in the enteric nervous system (Rugiero
et al., 2003). NaV1.9 is a biophysically unique sodium channel
which generates TTX-resistant currents that have very slow
gating kinetics (Dib-Hajj et al., 2002). The current generated by
NaV1.9 is ‘persistent’ and can be activated at potentials close to
resting membrane potential (60 mV). Although the activation
kinetics are too slow to contribute to the up-stroke of an action
potential, the channel acts as a modulator of membrane excitabil-
ity by contributing regenerative inward currents over a strategic
membrane potential range both negative to, and overlapping with
the voltage-threshold for other transient sodium channels.
While a selective blocker of NaV1.9 does not exist at present,
SCN11A knockout mice exhibit a clear analgesic phenotype (Priest
et al., 2005; Amaya et al., 2006), confirming NaV1.9 is an import-
ant player in generating hyperalgesia in inflammatory pain states.
This appears to be explicable by changes in the properties of distal
primary afferents. The response to inflammatory mediators is sup-
pressed in NaV1.9 knockout mice consistent with the immunocyto-
chemical localization of the channel at unmyelinated nerve
endings (Black and Waxman, 2002; Padilla et al., 2007), and
the remarkable functional plasticity of the current, known to be
under G-protein pathway control via protein kinase C (Baker
et al., 2003; Baker, 2005). Overall, therapeutically targeting
NaV1.9 may help regulate pain thresholds following inflammation
or injury.
b-Subunits of voltage-gated
sodium channels
b-Subunits of VGSCs belong to the immunoglobulin superfamily of
cell adhesion molecules and associate with -subunits in two ways:
covalently in the case of b2 and b4 subunits and non-covalently
for b1 and b3 subunits (Patino and Isom, 2010). VGSC b-subunit
expression is widespread both in excitable and non-excitable
tissues (Patino and Isom, 2010). Although reported effect sizes
vary, b-subunits shift the voltage-dependent gating of VGSC in
heterologous expression systems (Zhao et al., 2011). In humans,
mutations in b-subunits have been linked to numerous cardiac and
epilepsy related diseases (Table 1). Heterozygous b1 mutations
have been identified in seven families with generalized epilepsy
with febrile seizures plus (Scheffer et al., 2007), (4–6% of
generalized epilepsy with febrile seizures plus patients) with
the most common mutation being C121W, which leads to
impaired trafficking of VGSC to the axon initial segment
(Wimmer et al., 2010). A human SCN1B epilepsy-related mutation
(G257R) unique to a splice variant of b1BA has been proposed to
contribute to epilepsy through a mechanism that includes intracel-
lular retention b1 resulting in aberrant neuronal path-finding
(Patino et al., 2011). Mice heterozygous for b1 (C121W) dis-
played behavioural arrest at elevated core temperatures and
enhanced axon initial segment excitability, which is proposed to
be due to a hyperpolarized shift in the voltage dependence of
activation of VGSC expressed at the axon initial segment
(Wimmer et al., 2010). Mutations in all four b-subunits have
been linked to cardiac pathologies including Brugada syndrome
(b1 and b3), atrial fibrillation (b1, b2 and b3), ventricular fibrilla-
tion (b3) and long QT syndrome (b4) (Table 1). Mutations in b3
and b4 have also been linked to sudden infant death syndrome
(found in 1% of cases) due to reduced peak sodium current
through NaV1.5 and enhanced ‘late sodium current’ (Tan et al.,
2010).
Expression levels of VGSC b-subunits vary in different patho-
logical conditions (nerve injury, pain, Huntington’s disease) and
knockout models of VGSC b-subunits display pain, epilepsy and
ataxia phenotypes (Patino and Isom, 2010), suggesting that the
range of VGSC b-subunit roles in pathological conditions may be
wider than known. Interestingly, recent reports also show that the
affinity and efficacy of VGSC inhibitors can be dramatically altered
by changing b-subunit expression levels (Uebachs et al., 2010;
Wilson et al., 2011) and that b-subunit expression levels change
during diseases such as Huntington’s disease (mouse model)
(Oyama et al., 2006) and after nerve injury (Pertin et al., 2005).
It remains to be seen whether this altered pharmacology of -
complexes can be utilized to produce VGSC blockers with higher
selectivity and efficacy in vivo.
VGSC b-subunits also interact with the extracellular matrix as
well as the cytoskeleton and intracellular signalling molecules
(Isom, 2002; Brackenbury and Isom, 2011). Enzymatic cleavage
leads to production of a soluble ectodomain and membrane
bound C-terminal fragment, which have been implicated in the
regulation of cell–cell contact and neurite outgrowth (Wong
et al., 2005). The b4-subunit was recently identified as a novel
substrate of the b-secretase, BACE1, an enzyme implicated in the
pathogenesis of Alzheimer’s disease (Huth et al., 2011). In BACE1
knockout mice, the decay of the resurgent sodium current re-
corded from Purkinje cells was found to be slowed and could be
modelled as a decrease in open pore block consistent with pro-
teolytic modification of b4.
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Sodium channel trafficking
and disease
The pivotal role of sodium channels in electrical signalling requires
targeting of VGSCs to the correct cellular location. High channel
densities of VGSCs can be found at the axon initial segment and
nodes of Ranvier as part of complex protein aggregates (Hedstrom
and Rasband, 2006). Cytoplasmatic proteins regulate expression
and function of VGSCs through binding to the intracellular
domain of VGSCs, that are, in contrast to the extracellular
domain, relatively divergent (Wood et al., 2004). To date, several
studies have focused on identifying VGSC-associated proteins of
which some are involved in trafficking (Diss et al., 2004; Shao
et al., 2009; Leterrier et al., 2010). For example NaV1.8 requires
the expression of the annexin p11 subunit, which binds to the
N-terminal region of the channel to facilitate cell-surface expres-
sion of the channel (Okuse et al., 2002). Nerve growth factor
upregulation of functional NaV1.8 expression, important in
inflammatory pain appears to be indirectly mediated through
enhanced p11 expression and trafficking (Okuse et al., 2002;
Poon et al., 2004). In addition, the interaction of the
N-terminus of NaV1.6 with microtubule-associated protein
Map1b facilitates trafficking of NaV1.6 to neuronal surfaces
(O’Brien et al., 2012).
A variety of protein kinases have been shown to regulate the
trafficking of VGSCs to the cell membrane or to specialized mem-
brane domains, such as lipid rafts (reviewed in Shao et al., 2009).
Stimulation of the b2-adrenergic receptor leads to localization of
cardiac NaV1.5 to caveolin-enriched membrane domains resulting
in increased function and thereby possibly promoting cardiac ar-
rhythmias (Yarbrough et al., 2002). Moreover, trafficking of intra-
cellular pools of the sensory neuron-specific VGSCs NaV1.8 and
NaV1.9 has been implicated in enhanced pain sensitivity (Dib-Hajj
et al., 2010).
The co-factors required for NaV1.9 expression have not been
defined, but this channel can only be functionally expressed in
dorsal root ganglion neurons where it rescues the expression of
persistent current in NaV1.9 knockout neurons (Ostman et al.,
2008).
A number of VGSC mutants found in several human diseases
have been found to be trafficking-deficient and may give insights
into key protein regions/domains important for the regulation of
VGSC trafficking (Table 1). Trafficking defects may arise due to
improper protein folding or altered binding to essential chaperones
within the endoplasmic reticulum, ultimately leading to endoplas-
mic reticulum retention and/or protein degradation. Alternatively,
VGSC domains that are crucial for binding to associated proteins
regulating VGSCs localization/functioning may be affected. An
important family of scaffolding proteins, ankyrins, is responsible
for the localization of structurally diverse membrane-associated
and cytosolic protein, including VGSCs. Ankyrin-G is important
in clustering NaV1.2 and NaV1.6 into nodes of Ranvier and axon
initial segments (Jenkins and Bennett, 2001; Garrido et al., 2003).
A nine-residue motif has been characterized in the DII–III loop that
is critical for ankyrin-G binding. This sequence is highly conserved
within all VGSC isoforms and is almost identical between NaV1.2,
NaV1.5 and NaV1.6 (Lemaillet et al., 2003). Mutation of the
ankyrin-G binding site of NaV1.6 prevents clustering at the axon
initial segments (Gasser et al., 2012). A mutation associated with
Brugada syndrome has been found within this ankyrin-G-binding
motif of NaV1.5. This mutation (E1053K) abolished ankyrin-G
binding resulting in a loss of membrane expression in cardiac
myocytes (Mohler et al., 2004). Other Brugada syndrome muta-
tions in NaV1.5 have been shown to be associated with defective
trafficking/surface localization emphasizing the importance of cor-
rect targeting of this protein for cardiac function (Baroudi et al.,
2001, 2002; Kyndt et al., 2001; Valdivia et al., 2002; Bezzina
et al., 2003; Herfst et al., 2003; Ruan et al., 2010).
In patients with long QT syndrome, mutations in NaV1.5-
associated genes have been found, such as ankyrin-B and
SCN4B (Saenen and Vrints, 2008). b-Subunits regulate the surface
density and the biophysical properties of the channel complex
(Shao et al., 2009) and knockout mice lacking b2 subunit show
reduced VGSC surface expression (Chen et al., 2002). Moreover,
a recent report showed that a loss-of-function mutation of the
SCN3B-encoded channel b3 subunit (Navb3–V54G) is associated
with a case of idiopathic ventricular fibrillation. This mutation
caused a trafficking defect of NaV1.5 to the plasma membrane
(Valdivia et al., 2010). Conversely, b-subunits have also been
shown to rescue a trafficking-defective NaV1.1 mutant (Rusconi
et al., 2007).
Four mutations in the SCN1B gene have been described that
lead to an inherited generalized epilepsy with febrile seizures plus.
Both mutations occur in a domain of the b1 subunit that is im-
portant for the regulation of the subcellular localization of VGSCs
within neurons (Wimmer et al., 2010). An epilepsy causing SCN1A
loss-of-function mutation within the region of the C-terminal cyto-
plasmatic domain (M1841T) that is involved in interactions with
accessory subunits has been identified as trafficking defective.
Importantly, trafficking of this mutant could be rescued by mod-
ulatory proteins, such as b-subunits, calmodulin or G protein b23
and the anti-epileptic drug phenytoin (Rusconi et al., 2007).
However, phenytoin cannot be used therapeutically as it also
blocks channel function.
The broadly expressed 20 amino acid IQ motif also found in
VGSCs binds to the ubiquitously expressed Ca2 + -sensing protein
calmodulin. Mutation of the NaV1.4 calmodulin-binding IQ motif
showed that this domain is indispensable for normal channel
expression and functioning (Biswas et al., 2008). A mutation of
SCN2A that reduced affinity for calcium-bound calmodulin was
observed in a patient with autism (Weiss et al., 2003). Finally, a
recent study has identified two novel non-truncating missense mu-
tations in families with congenital insensitivity to pain that were
mapped within the pore domain of SCN9A. These mutations cause
complete loss-of-function as well as membrane expression of the
channel (Cox et al., 2010).
There are no effective drugs in use that target trafficking of
VGSC. However, some reports have shown that mexiletine, a
drug used to inhibit persistent sodium current and to shorten
QT interval, rescues trafficking in defective SCN5A mutants
(Valdivia et al., 2002; Ruan et al., 2010). The rescue of trafficking
of these mutants, however, counteracts the effectiveness of the
drug as the increased trafficking may exacerbate the QT
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prolongation due to increased expression of the mutant protein. In
contrast, phenytoin not only rescues a trafficking-defective SCN1A
mutant but also blocks the channel (Rusconi et al., 2007). Thus,
drugs that can act as folding chaperones to rescue mutant protein,
but do not block channel function, are required.
Although effective drugs have yet to be designed to modulate
VGSC expression by interfering with the trafficking pathway, some
promising results have been obtained with the anti-epileptic and
anti-nociceptive drug gabapentin and its derivatives. These drugs
exert their effect primarily via inhibition of trafficking of the
voltage-gated 22 calcium channel subunit (Heblich et al.,
2008; Hendrich et al., 2008) indicating that drugs targeting traf-
ficking may be useful in VGSC-related pathologies.
Toxins as useful tools to
understand voltage-gated
sodium channel function
and pharmacology
Toxins have been useful in understanding the structural and mo-
lecular determinants of VGSC gating through their modifying ac-
tions on the gating of VGSCs (Catterall et al., 2007). At least six
toxin-binding sites (sites 1–6) for toxins have been localized to
specific regions of sodium channels. The site of interaction of a
number of more recently characterized toxins, including the inhibi-
tory mO-conotoxins and spider toxins, remains to be fully charac-
terized. Binding to these sites affects channel ion conduction or
gating, and sequence differences in the residues involved contrib-
ute to subtype specificity (Catterall, 2000). Site 1 toxins such as
TTX and the mO-conotoxins inhibit current, while most site 2–6
toxins enhance sodium current through effects on channel gating.
While channel enhancers have helped to characterize gating and
inactivation mechanisms of sodium channels, and the allosteric
interactions between toxin binding sites, these classes of toxins
invariably produce toxic effects at all doses.
The usefulness of toxins as clinically relevant drugs is limited in
part by their high molecular weights and lack of subtype specifi-
city. However, a peptide derived from tarantula venom, peptide
ProTx-II is two orders of magnitude more selective for NaV1.7
compared with other heterologously expressed VGSCs and
blocked action potential propagation in nociceptors (Schmalhofer
et al., 2008a). Moreover, a mO-conotoxin selectively blocks
NaV1.8 currents and chronic pain behaviour in animal models
(Ekberg et al., 2006).
Mechanisms of drug binding to
voltage-gated sodium channels
VGSCs, like other voltage-gated ion channels, can be differentially
modulated by compounds that bind selectively to distinct con-
formational states of the channels. Upon changes in membrane
potential, VGSCs undergo voltage-dependent gating that consists
of a succession of conformational transitions: non-conducting
closed states upon depolarization adopt an activated conducting
open state followed by open-state inactivation in which the flow
of ions through the channel pore is blocked by the movement of a
molecular ‘ball’ into the cytoplasmic side of the newly opened
pore (Armstrong and Hille, 1998) (Fig. 1). Repolarization of the
membrane leads to another conformational transition, the deacti-
vation gate (Kuo and Bean, 1994), which consists in a brief open-
ing of the channel before reaching the closed states again. Other
conformational states of VGSCs include closed-state inactivation
(Armstrong, 2006), slow inactivation and for some VGSCs the
‘resurgent current’ gate. Closed-state inactivation is engaged
upon small depolarizations (these allow the movement of the S4
voltage sensors in domains III and IV only, which is enough for the
inactivation particle to move into the pore before the channel
opens). Slow inactivation is reached during prolonged
depolarizations.
Extensive mutagenesis studies of VGSCs have identified the local
anaesthetic binding site as the intracellular surface of the S6 heli-
ces (Ragsdale et al., 1994, 1996), binding to which causes occlu-
sion of the pore. The modulated receptor hypothesis (Hille, 1977)
first predicted that the local anaesthetic binding site could be ac-
cessed via two distinct mechanisms: a hydrophilic pathway requir-
ing binding of the drug from the intracellular side during channel
opening and a hydrophobic pathway whereby local anaesthetics
can access the water filled pore directly. Indeed, the recent crystal
structure of the Arcobacter butzleri VGSC NavAb confirmed the
existence of hydrophobic fenestrations within the protein lipid
interface composed of fatty acyl chains (Payandeh et al., 2011,
2012). These observations suggest a molecular mechanism for
closed state and use/frequency-dependent inhibition of VGSCs.
Highly hydrophilic local anaesthetics have limited access to the
hydrophobic pathway and instead require opening of VGSCs,
allowing access of local anaesthetics to the pore and promoting
binding of local anaesthetics in the inactivated state. In this case
cumulative block occurs with high-frequency opening when dis-
sociation from the local anaesthetic binding site occurs with a time
constant slower than the association rate. This results in accumu-
lation of inhibition and makes potency dependent on opening fre-
quency. By contrast, neutral or hydrophobic local anaesthetics can
access the local anaesthetic binding site through both the hydro-
phobic pathway when the channel is in the closed state and the
hydrophilic pathway during channel opening, resulting in a com-
bination of tonic and use-dependent blocking properties. In add-
ition, quaternary amines such as QX-222 or QX-314 may have
restricted access to the local anaesthetic binding site in accordance
with the guarded receptor hypothesis (Starmer and Hollett, 1985),
which may also contribute to use-dependent block. Many neuro-
logical pathological conditions result from neurons firing action
potentials at higher frequencies than normal, which lead to
these cells displaying a tonically depolarized membrane potential.
Therefore, voltage-dependent compounds that exhibit frequency-
dependent inhibition of VGSCs are desirable as they will tend to
only target VGSCs in affected areas, leaving healthy tissues safe.
The voltage dependence of VGSC ligands along with their phar-
macokinetic properties (on and off rates) is critical in determining
the mode of action of these compounds. Chemical entities with
affinity for the resting state of VGSCs, like TTX, simply bind to the
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extracellular regions of VGSCs, block the passage of ions and
cannot be removed by either changing the membrane voltage
or the gating of the channel. On the contrary, compounds with
affinity for the open-inactivated state need channel opening, and
therefore membrane depolarization, to bind to the inner pore of
VGSCs. The pharmacokinetic properties of these ligands determine
the optimal frequency at which blockade is strongest: slow dissoci-
ation rates promote use-dependent block at low frequencies,
whereas fast off rates favour block at high frequencies. In other
words, voltage-dependent drugs that dissociate quickly from
VGSCs when the membrane potential is returned to resting
values upon action potential repolarization, such as anti-epileptic
VGSC blockers, are best at affecting high-frequency firing as
observed in epileptic conditions. On the contrary, voltage-
dependent compounds that dissociate more slowly, such as
anti-arrhythmic and local anaesthetic VGSC blockers, tend to be
more effective in blocking low-frequency firing.
Sodium channel targeted drugs
Voltage-gated sodium channel blockers
as local anaesthetics
Cocaine was one of the first topical anaesthetics used by humans.
Although cocaine is well known as a serotonin–norepinephrine–
dopamine reuptake inhibitor, it also has VGSC blocking properties
(Ruetsch et al., 2001). Over the years, novel VGSC blockers that
can be used as local anaesthetics have been synthesized that
target VGSC more specifically, have higher efficacy and have
fewer side-effects. Currently, many different VGSC blockers are
used as local anaesthetics such as lidocaine, bupivacaine and ropi-
vacaine (Ruetsch et al., 2001). Local anaesthetics are weak bases
that require to be injected as hydrochloride salts in acid solution to
be dissolved. At the site of injection, where the pH is higher, local
anaesthetics dissociate according to their pKa and release a free
base. The free base is able to cross the nerve cell membrane and
once inside the nerve, it becomes re-ionized due to the lower
cytoplasmic pH and is unable to diffuse out of the cell (ion
trapping).
The most common systemically applied local anaesthetics are
lidocaine and mexiletine, which have been demonstrated to be
effective drugs in treating neuropathic pain in controlled clinical
studies (Challapalli et al., 2005). These anti-nociceptive effects of
local anaesthetics can be observed even at plasma concentrations
that would be too low to physiologically block nerve conduction.
However, these low concentrations of local anaesthetics are still
sufficient to block/attenuate impulse generation/ectopic dis-
charges that cause pain while nerve conduction is unaffected
(Mao and Chen, 2000). Importantly, the anti-inflammatory as
well as anti-nociceptive effects of local anaesthetics cannot be
explained solely by their action on VGSCs (Hollmann and
Durieux, 2000; Mao and Chen, 2000). For example, systemic lido-
caine enhances spinal inhibitory glycinergic neurotransmission in-
dependent of VGSC inhibition (Muth-Selbach et al., 2009).
Subtype selective blockers to treat pain
NaV1.7 and NaV1.8 have expression patterns restricted predomin-
antly to the PNS and are both essential for normal pain transmis-
sion. Selective antagonists (Table 2) of these channels therefore
make attractive targets for the treatment of pain due to the
reduced chance of CNS or cardiac side-effects (although NaV1.8
may play a role in cardiac conduction). A-803467 is a NaV1.8
selective small molecule showing selective block of both recom-
binant and native NaV1.8 currents (Jarvis et al., 2007). In vitro
studies performed on isolated small-diameter dorsal root ganglion
neurons have demonstrated that A-803467 blocks NaV1.8 currents
in a voltage-dependent manner and inhibits action potential firing.
A-803467 shows efficacy in alleviating acute mechanical pain,
inflammatory thermal hyperalgesia and neuropathic pain in
rodents (Jarvis et al., 2007). These behavioural data are consistent
with data showing systemic injection of A-803467 decreases both
mechanically evoked and spontaneous firing of spinal neurons in
nerve-injured rats (McGaraughty et al., 2008). The identification
of this compound provides an important proof of concept that it is
possible to develop isoform-specific blockers of sodium channels
that are analgesic. Following the development of the NaV1.8
selective blocker A-830467, Abbott Labs have succeeded in
developing an orally active preparations based on a modified
structure of A-830467 that is effective in rodent models of neuro-
pathic pain (Drizin et al., 2008). These compounds generally
inhibited NaV1.8 with IC50s in the sub-micromolar range and
had some selectivity for NaV1.8 over other Nav isoforms with
the best compound displaying a 5-fold and 20-fold greater po-
tency for NaV1.8 over NaV1.2 and NaV1.5, respectively.
Importantly, this class of drugs shows improved effects after oral
application and better safety profiles than currently clinically used
sodium channel blockers such as mexiletine and lamotrigine (Drizin
et al., 2008).
NaV1.7 blockers have also been developed, but the benzazepi-
none structures have equipotent actions on Nav 1.2 and 1.5, sug-
gesting that side-effects may be an issue (Williams et al., 2007).
Currently, specific NaV1.7 blockers are being tested by a
number of companies in human trials. For example, Convergence
Pharmaceuticals are evaluating a NaV1.7 inhibitor in phase II trials
of trigeminal neuralgia.
A selective small molecule NaV1.7 blocker (BZP) is an example
of an approach to facilitate inhibition of peripherally expressed
VGSCs by designing compounds that poorly penetrate the CNS
(McGowan et al., 2009). BZP was demonstrated to have
anti-nociceptive effects in animal models of inflammatory and
neuropathic pain after oral administration, while inducing fewer
CNS-related side-effects compared to mexiletine.
State-dependent acting agents to
treat pain
Biophysical characterization of rare gain-of-function mutations af-
fecting pain signalling has provided us with invaluable insight into
the way various sodium channel blocking drugs differentially
modulate the transition between the states of VGSCs. NaV1.7
mutations in primary erythromelalgia and paroxysmal extreme
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pain disorder exhibit gain-of-function. Interestingly, patients with
paroxysmal extreme pain disorder respond favourably to carba-
mazepine treatment, while carbamazepine is generally ineffective
in patients with inherited primary erythromelalgia (Dib-Hajj et al.,
2007; Fertleman et al., 2007). Paroxysmal extreme pain disorder
mutations enhance recovery from inactivation and mutant chan-
nels can give rise to persistent and enhanced resurgent currents
(Dib-Hajj et al., 2008; Jarecki et al., 2008; Theile et al., 2011).
Carbamazepine specifically targets these deficits by shifting
the voltage dependence of fast inactivation towards more hyper-
polarized potentials and targets persistent currents while leaving
normal currents relatively unaffected. In contrast, in most patients
with inherited primary erythromelalgia, negative shifts in the
voltage dependence of activation are observed. These altered
properties of the channel are not affected by carbamazepine.
In addition, sodium channel inhibitors such as riluzole that
effectively target persistent currents and accelerate the rate of
inactivation display enhanced efficacy towards inhibiting
Navb4-peptide-mediated resurgent currents and also paroxysmal
extreme pain disorder mutant currents (Theile et al., 2011). In
agreement with this view, it was recently demonstrated that
patients with primary erythromelalgia with a (V400M) mutation
in SCN9A also display a modified VGSC fast inactivation and
can be successfully treated with carbamazepine (Fischer et al.,
2009).
The local anaesthetics mexiletine and lidocaine are effective in
some cases of primary erythromelalgia (Iqbal et al., 2009; Kuhnert
et al., 1999). Importantly, the effectiveness of these drugs can be
affected by the causative mutation. For example, a specific pri-
mary erythromelalgia causing mutation (V872G) can lead to
increased use-dependent block of this mutant channel, indicating
some patients might have a favourable response to mexilitine
(Choi et al., 2009). On the contrary, another primary erythrome-
lalgia mutation (N395K) has been found to cause a loss in lido-
caine sensitivity and this was associated with ineffectiveness of
treatment with Las (Sheets et al., 2007).
Lacosamide is a novel amino acid derivative with anti-
convulsant activity that is also effective as an analgesic (Stohr
et al., 2006) in several animal models of neuropathic pain
(Beyreuther et al., 2006, 2007a) and as a therapy for painful dia-
betic neuropathy (Doty et al., 2007). Lacosamide selectively en-
hances sodium channel slow inactivation with no effects on fast
inactivation (Errington et al., 2008) as demonstrated on recombin-
ant NaV1.3, NaV1.7 and neuronal NaV1.8 currents (Sheets et al.,
2008). Slow inactivation is induced under conditions of sustained
depolarization and repeated firing, conditions relevant for the
pathophysiology of chronic pain. The difference in affinity of laco-
samide for binding inactivated channels rather than channels in
the resting state was much higher than that for carbamazepine
or lidocaine. Recently, it has been shown that lacosamide mediates
some actions on VGSC through binding to collapsin response
mediator protein 2 (now known as DPYSL2) and this interaction
with collapsin response mediator protein 2 results in lacosamide-
induced slowing of inactivation (Wang et al., 2010b). This
novel class of VGSC blockers, which targets VGSC channels in
specific conformations associated with certain pathologies, opens
a new avenue of drug development that may lead to blockers
of ‘pathological’ VGSCs. Recently, it has been shown that
uncoupling of collapsin response mediator protein 2 from
N-type voltage-gated calcium channels also suppresses inflam-
matory and neuropathic pain (Brittain et al., 2011). However,
the relative importance of lacosamide effects on VGSC and
voltage-gated calcium channels is uncertain (Wang and Khanna,
2011).
Alternative modes of action to treat pain
To limit the side-effects of VGSC blockers, one possibility is to
develop compounds that target VGSCs to the desired tissue only
(Clare, 2010). One example of such a drug is cyclopentane dicar-
boxamide CDA54, a non-selective VGSC blocker developed by
Merck (Shao et al., 2005). Oral administration of CDA54 is ef-
fective at reducing pain responses in models of inflammatory and
neuropathic pain (Shao et al., 2005; Brochu et al., 2006).
Importantly, after oral administration of CDA54 into rats, brain
homogenate concentrations were found to be 33-fold lower
than plasma concentrations, thus reducing the likelihood of side
effects caused by actions within the CNS. In addition, compound
54 showed less cardiotoxicity than mexiletine (Brochu et al.,
2006).
Transdermal drug application may be an advantageous way of
targeting the PNS. The effectiveness of this administration route
has been demonstrated by the success of lidocaine patches.
Lidocaine patches are approved for the relief of pain associated
with post-herpetic neuralgia and have proved efficacious in the
treatment of peripheral neuropathies, lower back pain, myofascial
pain, osteoarthritis, leg ulceration, erythromelalgia and carpal
tunnel syndrome (Nalamachu et al., 2006).
One often undesired effect of classic VGSC blockers such as
lidocaine and its derivatives is that they block action potential
firing not only in nociceptive neurons after perineural injection
but also in other neurons, thereby inhibiting tactile and mechanical
sensation as well as motor function. Thus, targeting derivates of
lidocaine specifically to nociceptive neurons, while leaving tactile
and mechanical sensation unaffected, is an attractive strategy to
treat pain. One strategy for selectively inhibiting nociceptors is
cell-specific targeting of the quaternary lidocaine-derivative
QX-314 to nociceptive neurons. QX-314 produces a long-lasting
non-selective neuronal block with a slow onset (Lim et al., 2007).
The slow onset of neuronal block is most probably linked to the
low membrane permeability of QX-314 reducing the capacity of
QX-314 to reach the intracellular blocking site of VGSCs. How-
ever, the transient receptor potential cation channel (TRPV1)
agonist capsaicin facilitates the selective cellular entry of QX-314
into nociceptive sensory neurons through TRPV1, which is select-
ively expressed in nociceptors (Binshtok et al., 2007). By combin-
ing QX-314 with other TRPV1 agonists such as lidocaine itself or
protons (lowering pH), similar effects can be achieved (Binshtok
et al., 2009; Liu et al., 2011; Roberson et al., 2011). One report
also showed that QX-314 itself acts as a TRPV1 agonist
(Rivera-Acevedo et al., 2011). Unfortunately, intrathecal applica-
tion of QX-314 causes serious irritation and death (Schwarz et al.,
2010) and is twice as toxic as lidocaine when applied systemically
in mice (Cheung et al., 2011). Activation of TRPV1 results in
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intense pain and does therefore not appear to be the most ap-
pealing route to affect analgesia through the use of sodium chan-
nel blockers.
Biologicals as the next
generation of analgesics
Over recent years, biological compounds such as peptides and
antibodies have begun to feed into drug discovery programmes
for many disease indications including pain. These include anal-
gesic peptides based on venom toxins, which interact with VGSC.
The perceived advantage of venom peptides over conventional
small molecule inhibitors is that the toxins are often highly
potent and efficacious (low nanomolar IC50s) and have a greater
potential for selectivity due to their larger drug target interface.
Subsequent mutagenesis of the wild-type toxin can then further
improve potency and strive to improve selectivity for a given
VGSC isoform. ProTx-II is a venom toxin from the tarantula
Thrixopelma prurient and has been reported to block NaV1.7
channels (IC50 = 0.3 nM) with 4100-fold selectivity over other
Nav isoforms (Middleton et al., 2002; Priest et al., 2007;
Schmalhofer et al., 2008a). ProTx-II was effective at reducing
C-fibre action potential firing frequency in an isolated skin nerve
preparation in which the nerve had been de-sheathed
(Schmalhofer et al., 2008b); however, no effect of ProTx-II was
observed with an intact nerve sheath indicating that this peptide
cannot access sodium channels in intact tissues. Intravenously
applied ProTx-II was also ineffective at reducing complete
Freund’s adjuvant-induced mechanical hyperalgesia. These data
confirm that targeting NaV1.7 with a potent selective inhibitor is
sufficient to dampen peripheral nociceptive drive (reduce firing of
C fibres); however, due to the low permeability of ProTx-II, it is
ineffective as an analgesic. Future toxin-derived analgesics tar-
geted to peripherally expressed proteins must therefore overcome
this limitation. Importantly, it is possible to use a herpes viral
vector to specifically deliver biologicals to sensory neurons of the
dorsal root ganglion (Fink et al., 2011).
Monoclonal antibodies targeted to essential pain pathway pro-
teins also have the potential to revolutionize analgesic drug dis-
covery due to their potential for high selectivity, high affinity
(femtomolar range), low cardiotoxicity and long half-life (monthly
subcutaneous injections are achievable). Monoclonal antibodies
targeted against nerve growth factor (e.g. tanezumab, Pfizer)
have successfully been used to treat chronic joint pain in osteo-
arthritic patients (Cattaneo, 2010). Polyclonal antibodies targeted
against the second or third extracellular loop of ion channels have
been successfully used as isoform selective channel blockers of
TRP channels (Klionsky et al., 2006; Naylor et al., 2008), VGSCs
(Chioni et al., 2005) and voltage-gated calcium channels (Liao
et al., 2008). However, to date there are no published records
of a therapeutically useful monoclonal antibody with ion channel
blocking function, although a patent has been filed (US2011/
0135662 A1) which describes a NaV1.7 (E3 loop) targeted rabbit
antibody which inhibits NaV1.7 currents in a frequency-dependent
manner, indicating that this approach may be valid.
Voltage-gated sodium channel
blockers in neurological
diseases
Voltage-gated sodium channel blockers
as anti-epileptic drugs
Phenytoin and carbamazepine are the most widely used com-
pounds to treat epilepsy. Both these drugs act in a
state-dependent manner and slow the recovery from inactivation,
thereby reducing the availability of channels for subsequent open-
ing (Rogawski and Loscher, 2004). Phenytoin and carbamaze-
pine are both effective in combating partial and generalized
tonic–clonic seizures in humans and in animal models of these
conditions (Perucca and Tomson, 2011). However, phenytoin
and carbamazepine do not show efficacy against absence seizures
(very brief generalized epileptic seizures of sudden onset and
termination) both in humans and in the animal models of this
condition (Dreifuss, 1983; Mantegazza et al., 2010). Phenytoin
is most effective at depolarized membrane potentials and
high-frequency action potential firing. The state dependence of
phenytoin causes minimal effects on cognitive functions
(low-frequency firing). Carbamazepine displays the same
pharmacological properties as phenytoin (VGSC specificity, volt-
age and state dependence). However, carbamazepine binds
VGSCs less effectively, but with a much faster rate than pheny-
toin, rendering carbamazepine more effective in blocking high-
frequency firing (Mantegazza et al., 2010). These differences in
properties might explain why some epileptic patients respond
better to one or the other drug if they carry different VGSC
mutations.
Lamotrigine, like phenytoin and carbamazepine, is effective
against partial and generalized tonic–clonic seizures and also
shows efficacy for the treatment of absence seizures and
Lennox–Gastaut syndrome, a rare and intractable form of child-
hood epilepsy associated with learning difficulties. The mode of
action of lamotrigine on VGSCs is similar to that of phenytoin and
carbamazepine (voltage and use dependence). However, lamotri-
gine also acts on other molecular targets, such as the
hyperpolarization-gated cationic current Ih in dendrites of pyram-
idal neurons (Poolos et al., 2002), N- and P-type voltage-gated
Ca2 + channels in cortical neurons (Stefani et al., 1996) and neo-
cortical potassium currents (Zona et al., 2002). Therefore, the
anti-epileptic action of lamotrigine may have a different biophys-
ical basis to carbamazepine and phenytoin.
Topiramate, a sulphamate derivative of the naturally occurring
sugar D-fructose, is another broad-spectrum anti-epileptic drug
prescribed in cases of partial and generalized tonic–clonic seizures.
It blocks both VGSCs and voltage-gated Ca2 + channels and en-
hances potassium channel activity (Shank and Maryanoff, 2008).
Interestingly, the action of topiramate on VGSCs consists of slow-
ing down the opening of the channels and protein kinase C acti-
vation limits the effect of topiramate of blocking persistent sodium
currents (Curia et al., 2004).
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Introduced as an anti-epileptic drug in 1962, valproate has an
even more extensive range of pharmacological actions, being ef-
fective against partial and generalized tonic–clonic seizures, ab-
sence seizures, and myoclonic seizures. Valproate is a widely
prescribed anti-epileptic drug, in both adults and children, and
its success is likely to be due to modes of actions different from
blocking VGSCs. However, valproate selectively inhibits persistent
sodium currents over transient ones in neocortical and sympathetic
neurons (Taverna et al., 1998; Lamas et al., 2009), although the
exact mechanism remains unknown. In part, its therapeutic effects
are caused by increases in the turnover of GABA, inhibition of
NMDA (N-methyl-D-aspartic acid) receptors and reduction in
gamma-hydroxybutyrate release (Maitre, 1997).
Riluzole was first developed as an anti-epileptic drug but is now
used as the first-in-line drug for treatment of amyotrophic lateral
sclerosis. It has neuroprotective effects due to blockade of VGSCs
on presynaptic terminals and enhancing glutamate uptake by
astrocytes thereby inhibiting glutamatergic transmission. Addition-
ally, riluzole has been demonstrated recently to protect against
cardiac ischaemia and reperfusion injury by inhibiting persistent
sodium currents and is now being tested as a possible treatment
for psychiatric disorders (Pittenger et al., 2008; Weiss et al.,
2010).
Voltage-gated sodium channel blockers
for the treatment of migraine
Migraine is thought to originate from the activation of meningeal
and blood vessel nociceptive fibres, in conjunction with neuro-
genic inflammation and a change in central pain modulation
(Kalra and Elliott, 2007). In common with epilepsy, migraine is
characterized by recurrent episodes of nervous system dysfunction
with a return to baseline between attacks. Rare forms of familial
migraine are caused by mutation of SCN1A (Dichgans et al.,
2005; Vahedi et al., 2009). Migraine is treated with a
wide range of drugs, including tryptans that, through their agonist
effects on serotonin receptors, block the release of vasoactive
neuropeptides such as CGRP. Other treatments include the use
of non-steroidal anti-inflammatory drugs, anti-depressants and
calcium channel blockers (Bolcskei et al., 2009). Epilepsy is a
co-morbid condition of migraine. Several anti-epileptic drugs
targeting VGSCs have been tested for efficacy in migraine con-
ditions. Anti-epileptic compounds, such as valproate, topiramate
and lamotrigine, which act through VGSC, have been shown to
be effective at reducing the frequency of migraine attacks.
However, these drugs all act on other targets as well and there-
fore their therapeutic effect may be unrelated to their effect on
VGSCs (Calabresi et al., 2007). It is important to note that
use-dependent selective VGSC blockers, such as phenytoin and
carbamazepine, have not been documented to be efficacious
against migraine attacks (Rogawski and Loscher, 2004). Finally,
intranasal application of the local anaesthetic and anti-arrhythmic
compound lidocaine was reported to be an effective treatment
for some refractory migraines (Kudrow et al., 1995; Bolcskei
et al., 2009).
Voltage-gated sodium channel blockers
in neurodegenerative disorders and
neuroinflammation
Multiple sclerosis is a condition that may be linked to an autoim-
mune reaction. However, drug treatment to suppress immune
responses is of limited effectiveness. Neurodegeneration as a
consequence of progression of multiple sclerosis also involves
the activation of VGSCs (Smith, 2007). In particular, demyelination
of axons that occurs in patients with multiple sclerosis leads
to ectopic action potential firing that is caused by slow
sodium-dependent membrane potential oscillations (Kapoor
et al., 1997).
VGSCs have also been implicated in anoxia/injury-induced
neurodegeneration. Energy loss leads in part to persistent
sodium currents that cause an increase in axonal intracellu-
lar sodium leading to membrane depolarization and further
activation of VGSCs. These events promote the reversal of
Na +/Ca2 + exchanger and overload of axonal calcium (Stys,
2004).
VGSC blockers such as TTX, lidocaine, procaine, mexiletine,
phenytoin and carbamazepine protect against white matter
axonal damage in multiple sclerosis models (Waxman et al.,
1994a; Carter, 1998; Hewitt et al., 2001; Kapoor et al., 2003;
Black and Waxman, 2008). These protective effects can be
observed at concentrations that do not compromise the conduc-
tion of action potentials. Lidocaine and flecainide can also protect
axons from nitric oxide-triggered degeneration (Kapoor et al.,
2003). However, withdrawal of phenytoin or carbamazepine in
experimental autoimmune encephalomyelitis, a mouse model for
multiple sclerosis, resulted in increased inflammatory infiltrate,
worsening of symptoms and high incidence of mortality, leading
to the suspension of clinical trials (Black and Waxman, 2008). In
other trials, lamotrigine did not positively affect clinical outcome
measures of patients with secondary progressive multiple sclerosis
(Kapoor et al., 2010).
Other clinical trials involving a combined therapy with interferon
b1a and topiramate, riluzole and lamotrigine, respectively, are still
ongoing (Conway and Cohen, 2010). Thus, whether VGSC block-
ers will ultimately provide an effective new strategy for the treat-
ment of multiple sclerosis is unclear.
Effects of VGSC blockers might also occur through inhibition of
phagocytic functions of microglia. Expression of NaV1.6 is
upregulated in activated microglia and inhibition of VGSC reduces
their phagocytic capacity and reduces inflammatory cells infiltra-
tion in brain tissue of mice with experimental autoimmune en-
cephalomyelitis (Craner et al., 2005)
NaV1.5 is present in late endosomes of human macrophages,
which play an important role in phagocytosis. NaV1.6 is also ex-
pressed in macrophages where it associates with the cytoskeleton,
possibly aiding macrophage motility (Carrithers et al., 2007).
VGSCs were also shown to have a role in T-lymphocyte motility
(Fraser et al., 2004). However, given the possible side-effects, the
value of VGSC blockers to modulate immune responses is unclear
(Roselli et al., 2006).
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Voltage-gated sodium channel blockers
in neuromuscular disorders
Currently, 12 channelopathies affecting skeletal muscle have been
described. All five VGSC channelopathies affecting skeletal muscle
are found in SCN4A/NaV1.4 (Jurkat-Rott et al., 2010). These
channelopathies, as described earlier, are classified as potassium-
aggravated myotonia, paramyotonia congenita, hyperkalaemic
periodic paralysis, hypokalaemic periodic paralysis and a form of
congenital myasthenic syndrome. Depending on the functional
consequence of the mutation (gain- or loss-of-function), treat-
ment options are to either use VSGC blockers to directly
block the channel or to reduce the fraction of inactivated chan-
nels by restoring the skeletal muscle membrane potential
(Jurkat-Rott et al., 2010). Pharmacological treatment in myotonia
is aimed at decreasing muscle stiffness by mitigating the invol-
untary action potential bursts without blocking voluntary
high-frequency muscle stimulation (Jurkat-Rott et al., 2010).
VGSC blockers reduce muscle stiffness in potassium-aggravated
myotonia and paramyotonia congenita by promoting the inacti-
vated state of NaV1.4 by inducing a hyperpolarized shift in
steady-state inactivation and by prolonging recovery time from
inactivation. VSGC blockers such as mexiletine, flecainide and
other lidocaine analogues can reduce repetitive firing of action
potential because of their use-depended properties, a mechan-
ism that leads to a preferential action on channels with patho-
genic gain-of-function mutations (Mohammadi et al., 2005).
Symptoms of muscle weakness are often caused by other
pathogenic factors and cannot be treated sufficiently with
VGSC blockers. However, influencing potassium concentration
or blocking potassium channels have been proven to be beneficial
(Jurkat-Rott et al., 2010). Burge and Hanna (2012) performed a
more detailed analysis of mechanisms and therapeutic options in
neuromuscular disorders.
Voltage-gated sodium channel
blockers in non-neurological
diseases
Voltage-gated sodium channel blockers
as anti-arrhythmic drugs
VGSCs are important therapeutic targets in the management of
cardiac arrhythmias. According to the Singh Vaughan Williams
classification (Walker, 2006), the group of anti-arrhythmic
drugs is subdivided into four categories depending on
whether they block VGSCs, b-adrenergic receptors, potassium
channels or Ca2 + channels. Class I anti-arrhythmics are
primarily VGSC blockers that are further subdivided into three
subclasses (Nattel, 1993), based upon their effect on the
length of the action potential. VGSCs blockers as anti-arrhythmic
drugs have been discussed extensively previously (Ganjehei
et al., 2011)
Potential dangers of voltage-gated
sodium channel blockers on human
development
A missense mutation in the SCN9A gene encoding NaV1.7 has been
linked to abnormal limb development (Hoeijmakers et al., 2012).
Some VGSC blockers may have teratogenic effects. Anti-epileptic
medication during pregnancy might elevate the risk for congenital
malformations, particularly when the treatment involves multiple
compounds and/or valproate (Morrow et al., 2006). Anti-epileptic
treatment with valproate during pregnancy was also linked to sig-
nificantly lower intelligence in children (Bromley et al., 2009).
Lacosamide is not used in young children because it was demon-
strated to interact with the collapsin response mediator protein 2,
which is involved in neuronal differentiation and control of axonal
growth (Beyreuther et al., 2007b; Wang et al., 2010b).
Conclusions and future
directions
Sodium channel blockers originally derived from cocaine, such as
lidocaine, have been in clinical use for more than a century.
Progress in understanding the molecular basis of channel activity
and the mechanisms of action of some analgesic drugs that have
been found to act on sodium channels have provided a clear
framework in which to pursue medicinal chemistry approaches.
Toxins also provide important models for the development of
novel analgesic families, based on natural peptides or on organic
peptidomimetics. Recent advances in the development of orally
active small molecule-specific NaV1.8 blockers will eventually be
followed by antagonists of NaV1.7 and NaV1.9. In the meantime
the state-dependent blocker lacosamide looks set to join the
broad-spectrum sodium channel blockers already in clinical use
in Europe. While pain control and epilepsy are still the major
focus of interest in terms of sodium channel drug development,
it remains possible that indications ranging from autism to immune
disorders may be modulated by compounds targeted at sodium
channel activity. Manipulation of VGSCs in particular cell types is
desirable for many of these indications, as global channel blocking
is likely to have deleterious consequences. Topical application, tar-
geted delivery or drugs that lower functional channel expression
are all potential future approaches to these problems.
Acknowledgements
We thank members of the Molecular Nociception Group and
London Pain Consortium for helpful comments.
Funding
J.N.W. thanks the Medical Research Council, The Wellcome Trust
and the Biochemistry and Biotechnology Research Council for gen-
erous financial support. N.E. is supported by a Rubicon fellowship
of The Netherlands Organisation for Scientific Research (NWO).
Voltage-gated sodium channels Brain 2012: 135; 2585–2612 | 2603
R.W. is supported by a research fellowship (We 4860/1-1) from
Deutsche Forschungsgemeinschaft, Bonn, Germany.
References
Abrahamsen B, Zhao J, Asante CO, Cendan CM, Marsh S, Martinez-
Barbera JP, et al. The cell and molecular basis of mechanical, cold, and
inflammatory pain. Science 2008; 321: 702–5.
Ahmad S, Dahllund L, Eriksson AB, Hellgren D, Karlsson U, Lund PE,
et al. A stop codon mutation in SCN9A causes lack of pain sensation.
Hum Mol Genet 2007; 16: 2114–21.
Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated
sodium channel expressed by sensory neurons. Nature 1996; 379:
257–62.
Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, et al. The
tetrodotoxin-resistant sodium channel SNS has a specialized function in
pain pathways. Nat Neurosci 1999; 2: 541–8.
Alabi AA, Bahamonde MI, Jung HJ, Kim JI, Swartz KJ. Portability of
paddle motif function and pharmacology in voltage sensors. Nature
2007; 450: 370–5.
Alzheimer C, Schwindt PC, Crill WE. Modal gating of Na + channels as a
mechanism of persistent Na + current in pyramidal neurons from rat
and cat sensorimotor cortex. J Neurosci 1993; 13: 660–73.
Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J,
et al. The voltage-gated sodium channel Na(v)1.9 is an effector of
peripheral inflammatory pain hypersensitivity. J Neurosci 2006; 26:
12852–60.
Armstrong CM. Na channel inactivation from open and closed states.
Proc Natl Acad Sci USA 2006; 103: 17991–6.
Armstrong CM, Hille B. Voltage-gated ion channels and electrical excit-
ability. Neuron 1998; 20: 371–80.
Aurlien D, Leren TP, Tauboll E, Gjerstad L. New SCN5A mutation in a
SUDEP victim with idiopathic epilepsy. Seizure 2009; 18: 158–60.
Baker MD. Selective block of late Na + current by local anaesthetics in
rat large sensory neurones. Br J Pharmacol 2000; 129: 1617–26.
Baker MD. Protein kinase C mediates up-regulation of tetrodotoxin-
resistant, persistent Na + current in rat and mouse sensory neurones.
J Physiol 2005; 567: 851–67.
Baker MD, Bostock H. Low-threshold, persistent sodium current in rat
large dorsal root ganglion neurons in culture. J Neurophysiol 1997; 77:
1503–13.
Baker MD, Chandra SY, Ding Y, Waxman SG, Wood JN. GTP-induced
tetrodotoxin-resistant Na + current regulates excitability in mouse and
rat small diameter sensory neurones. J Physiol 2003; 548: 373–82.
Bant JS, Raman IM. Control of transient, resurgent, and persistent cur-
rent by open-channel block by Na channel beta4 in cultured cerebellar
granule neurons. Proc Natl Acad Sci USA 2010; 107: 12357–62.
Baroudi G, Acharfi S, Larouche C, Chahine M. Expression and intracel-
lular localization of an SCN5A double mutant R1232W/T1620M impli-
cated in Brugada syndrome. Circ Res 2002; 90: E11–6.
Baroudi G, Pouliot V, Denjoy I, Guicheney P, Shrier A, Chahine M. Novel
mechanism for Brugada syndrome: defective surface localization of an
SCN5A mutant (R1432G). Circ Res 2001; 88: E78–83.
Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD.
Efficacy and safety of oral lacosamide as adjunctive therapy in adults
with partial-onset seizures. Epilepsia 2007; 48.
Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism
for an inherited cardiac arrhythmia. Nature 1995; 376: 683–5.
Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide
in a rat model for painful diabetic neuropathy. Eur J Pharmacol 2006;
539: 64–70.
Beyreuther BK, Callizot N, Brot MD, Feldman R, Bain SC, Stohr T.
Antinociceptive efficacy of lacosamide in rat models for tumor- and
chemotherapy-induced cancer pain. Eur J Pharmacol 2007a; 565:
98–104.
Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U,
Stohr T. Lacosamide: a review of preclinical properties. CNS Drug
Rev 2007b; 13: 21–42.
Bezzina CR, Rook MB, Groenewegen WA, Herfst LJ, van der Wal AC,
Lam J, et al. Compound heterozygosity for mutations (W156X and
R225W) in SCN5A associated with severe cardiac conduction disturb-
ances and degenerative changes in the conduction system. Circ Res
2003; 92: 159–68.
Binshtok AM, Bean BP, Woolf CJ. Inhibition of nociceptors by
TRPV1-mediated entry of impermeant sodium channel blockers.
Nature 2007; 449: 607–10.
Binshtok AM, Gerner P, Oh SB, Puopolo M, Suzuki S, Roberson DP,
et al. Coapplication of lidocaine and the permanently charged
sodium channel blocker QX-314 produces a long-lasting nociceptive
blockade in rodents. Anesthesiology 2009; 111: 127–37.
Biswas S, Deschenes I, Disilvestre D, Tian Y, Halperin VL, Tomaselli GF.
Calmodulin regulation of Nav1.4 current: role of binding to the carb-
oxyl terminus. J Gen Physiol 2008; 131: 197–209.
Biton V. Clinical pharmacology and mechanism of action of zonisamide.
Clin Neuropharmacol 2007; 30: 230–40.
Black JA, Dib-Hajj S, McNabola K, Jeste S, Rizzo MA, Kocsis JD, et al.
Spinal sensory neurons express multiple sodium channel alpha-subunit
mRNAs. Brain Res Mol Brain Res 1996; 43: 117–31.
Black JA, Renganathan M, Waxman SG. Sodium channel Na(v)1.6 is
expressed along nonmyelinated axons and it contributes to conduc-
tion. Brain Res Mol Brain Res 2002; 105: 19–28.
Black JA, Waxman SG. Molecular identities of two tetrodotoxin-resistant
sodium channels in corneal axons. Exp Eye Res 2002; 75: 193–9.
Black JA, Waxman SG. Phenytoin protects central axons in experimental
autoimmune encephalomyelitis. J Neurol Sci 2008; 274: 57–63.
Bohle T, Benndorf K. Multimodal action of single Na + channels in myo-
cardial mouse cells. Biophys J 1995; 68: 121–30.
Boiko T, Rasband MN, Levinson SR, Caldwell JH, Mandel G, Trimmer JS,
et al. Compact myelin dictates the differential targeting of two sodium
channel isoforms in the same axon. Neuron 2001; 30: 91–104.
Bolcskei H, Farkas B, Kocsis P, Tarnawa I. Recent advancements in
anti-migraine drug research: focus on attempts to decrease neuronal
hyperexcitability. Recent Pat CNS Drug Discov 2009; 4: 14–36.
Bosmans F, Martin-Eauclaire MF, Swartz KJ. Deconstructing voltage
sensor function and pharmacology in sodium channels. Nature 2008;
456: 202–8.
Brackenbury WJ, Calhoun JD, Chen C, Miyazaki H, Nukina N, Oyama F,
et al. Functional reciprocity between Na + channel Nav1.6 and beta1
subunits in the coordinated regulation of excitability and neurite out-
growth. Proc Natl Acad Sci USA 2010; 107: 2283–8.
Brackenbury WJ, Isom LL. Na channel beta subunits: overachievers of
the ion channel family. Front Pharmacol 2011; 2: 53.
Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard C, Johnson PL, et al.
Suppression of inflammatory and neuropathic pain by uncoupling
CRMP-2 from the presynaptic Ca(2) channel complex. Nat Med
2011; 17: 822–9.
Brochu RM, Dick IE, Tarpley JW, McGowan E, Gunner D, Herrington J,
et al. Block of peripheral nerve sodium channels selectively in-
hibits features of neuropathic pain in rats. Mol Pharmacol 2006; 69:
823–32.
Bromley RL, Baker GA, Meador KJ. Cognitive abilities and behaviour of
children exposed to antiepileptic drugs in utero. Curr Opin Neurol
2009; 22: 162–6.
Burge JA, Hanna MG. Novel insights into the pathomechanisms of skel-
etal muscle channelopathies. Curr Neurol Neurosci Rep 2012; 12:
62–9.
Calabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM. Antiepileptic
drugs in migraine: from clinical aspects to cellular mechanisms.
Trends Pharmacol Sci 2007; 28: 188–95.
Caldwell JH, Schaller KL, Lasher RS, Peles E, Levinson SR. Sodium chan-
nel Na(v)1.6 is localized at nodes of ranvier, dendrites, and synapses.
Proc Natl Acad Sci USA 2000; 97: 5616–20.
Campbell RW. Mexiletine. N Engl J Med 1987; 316: 29–34.
2604 | Brain 2012: 135; 2585–2612 N. Eijkelkamp et al.
Cannon SC, Bean BP. Sodium channels gone wild: resurgent current from
neuronal and muscle channelopathies. J Clin Invest 2010; 120: 80–3.
Cardenas DD, Warms CA, Turner JA, Marshall H, Brooke MM,
Loeser JD. Efficacy of amitriptyline for relief of pain in spinal cord
injury: results of a randomized controlled trial. Pain 2002; 96: 365–73.
Carranza RD, Hamiwka L, McMahon JM, Dibbens LM, Arsov T, Suls A,
et al. De novo SCN1A mutations in migrating partial seizures of in-
fancy. Neurology 2011; 77: 380–3.
Carrithers MD, Chatterjee G, Carrithers LM, Offoha R, Iheagwara U,
Rahner C, et al. Regulation of podosome formation in macrophages
by a splice variant of the sodium channel SCN8A. J Biol Chem 2009a;
284: 8114–26.
Carrithers MD, Chatterjee G, Carrithers LM, Offoha R, Iheagwara U,
Rahner C, et al. Regulation of podosome formation in macrophages
by a splice variant of the sodium channel SCN8A. J Biol Chem 2009b;
284: 8114–26.
Carrithers MD, Dib-Hajj S, Carrithers LM, Tokmoulina G, Pypaert M,
Jonas EA, et al. Expression of the voltage-gated sodium channel
NaV1.5 in the macrophage late endosome regulates endosomal acid-
ification. J Immunol 2007; 178: 7822–32.
Carter AJ. The importance of voltage-dependent sodium channels in
cerebral ischaemia. Amino Acids 1998; 14: 159–69.
Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve
growth factor for the treatment of acute and chronic pain. Curr Opin
Mol Ther 2010; 12: 94–106.
Catterall WA. From ionic currents to molecular mechanisms: the structure
and function of voltage-gated sodium channels. Neuron 2000; 26:
13–25.
Catterall WA, Cestele S, Yarov-Yarovoy V, Yu FH, Konoki K, Scheuer T.
Voltage-gated ion channels and gating modifier toxins. Toxicon 2007;
49: 124–41.
Catterall WA, Goldin AL, Waxman SG. International Union of
Pharmacology. XLVII. Nomenclature and structure-function relation-
ships of voltage-gated sodium channels. Pharmacol Rev 2005; 57:
397–409.
Catterall W, Kalume F. NaV1.1 channels and epilepsy. J Physiol 2010;
588: 1849–59.
Cestele S, Scalmani P, Rusconi R, Terragni B, Franceschetti S,
Mantegazza M. Self-limited hyperexcitability: functional effect of a
familial hemiplegic migraine mutation of the Nav1.1 (SCN1A) Na +
channel. J Neurosci 2008; 28: 7273–83.
Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic
administration of local anesthetic agents to relieve neuropathic pain.
Cochrane Database Syst Rev 2005; CD003345.
Chambers JC, Zhao J, Terracciano CM, Bezzina CR, Zhang W, Kaba R,
et al. Genetic variation in SCN10A influences cardiac conduction. Nat
Genet 2010; 42: 149–52.
Chen C, Bharucha V, Chen Y, Westenbroek RE, Brown A, Malhotra JD,
et al. Reduced sodium channel density, altered voltage dependence of
inactivation, and increased susceptibility to seizures in mice lacking
sodium channel beta 2-subunits. Proc Natl Acad Sci USA 2002; 99:
17072–7.
Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al.
Genetic basis and molecular mechanism for idiopathic ventricular fib-
rillation. Nature 1998; 392: 293–6.
Cheung HM, Lee SM, Macleod BA, Ries CR, Schwarz SK. A comparison
of the systemic toxicity of lidocaine versus its quaternary derivative
QX-314 in mice. Can J Anaesth 2011; 58: 443–50.
Chioni AM, Fraser SP, Pani F, Foran P, Wilkin GP, Diss JK, et al. A
novel polyclonal antibody specific for the Na(v)1.5 voltage-gated
Na( + ) channel ’neonatal’ splice form. J Neurosci Methods 2005;
147: 88–98.
Choi JS, Zhang L, Dib-Hajj SD, Han C, Tyrrell L, Lin Z, et al.
Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation
showing use-dependent current fall-off. Exp Neurol 2009; 216:
383–89.
Chong MS, Libretto SE. The rationale and use of topiramate for treating
neuropathic pain. Clin J Pain 2003; 19: 59–68.
Clare JJ. Targeting voltage-gated sodium channels for pain therapy.
Expert Opin Investig Drugs 2010; 19: 45–62.
Conway D, Cohen JA. Emerging oral therapies in multiple sclerosis. Curr
Neurol Neurosci Rep 2010; 10: 381–8.
Corry B, Thomas M. Mechanism of ion permeation and selectivity
in a voltage gated sodium channel. J Am Chem Soc 2012; 134:
1840–6.
Cossette P, Loukas A, Lafreniere RG, Rochefort D, Harvey-Girard E,
Ragsdale DS, et al. Functional characterization of the D188V mutation
in neuronal voltage-gated sodium channel causing generalized epilepsy
with febrile seizures plus (GEFS). Epilepsy Res 2003; 53: 107–17.
Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K,
et al. An SCN9A channelopathy causes congenital inability to experi-
ence pain. Nature 2006; 444: 894–8.
Cox JJ, Sheynin J, Shorer Z, Reimann F, Nicholas AK, Zubovic L, et al.
Congenital insensitivity to pain: novel SCN9A missense and in-frame
deletion mutations. Hum Mutat 2010; 31: E1670–86.
Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, Black JA, et al.
Sodium channels contribute to microglia/macrophage activation and
function in EAE and MS. Glia 2005; 49: 220–9.
Craner MJ, Hains BC, Lo AC, Black JA, Waxman SG. Co-localization of
sodium channel Nav1.6 and the sodium-calcium exchanger at sites of
axonal injury in the spinal cord in EAE. Brain 2004; 127: 294–303.
Cummins TR, Dib-Hajj SD, Herzog RI, Waxman SG. Nav1.6 channels
generate resurgent sodium currents in spinal sensory neurons. FEBS
Lett 2005; 579: 2166–70.
Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in
nociception: implications for mechanisms of pain. Pain 2007; 131:
243–57.
Curia G, Aracri P, Sancini G, Mantegazza M, Avanzini G, Franceschetti S.
Protein-kinase C-dependent phosphorylation inhibits the effect of the
antiepileptic drug topiramate on the persistent fraction of sodium cur-
rents. Neuroscience 2004; 127: 63–8.
De Jonghe P. Molecular genetics of Dravet syndrome. Dev Med Child
Neurol 2011; 53 (Suppl 2): 7–10.
Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neur-
oma and DRG discharge without blocking nerve conduction. Pain
1992; 48: 261–8.
Dib-Hajj S, Black JA, Cummins TR, Waxman SG. NaN/Nav1.9: a sodium
channel with unique properties. Trends Neurosci 2002; 25: 253–9.
Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain:
Na v 1.7 and human pain disorders. Trends Neurosci 2007; 30:
555–63.
Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in
normal and pathological pain. Annu Rev Neurosci 2010; 33: 325–47.
Dib-Hajj SD, Estacion M, Jarecki BW, Tyrrell L, Fischer TZ, Lawden M,
et al. Paroxysmal extreme pain disorder M1627K mutation in
human Nav1.7 renders DRG neurons hyperexcitable. Mol Pain 2008;
4: 37.
Dib-Hajj SD, Fjell J, Cummins TR, Zheng Z, Fried K, LaMotte R, et al.
Plasticity of sodium channel expression in DRG neurons in the chronic
constriction injury model of neuropathic pain. Pain 1999; 83: 591–600.
Dib-Hajj SD, Tyrrell L, Black JA, Waxman SG. NaN, a novel
voltage-gated Na channel, is expressed preferentially in peripheral sen-
sory neurons and down-regulated after axotomy. Proc Natl Acad Sci
USA 1998; 95: 8963–8.
Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B,
Biskup S, et al. Mutation in the neuronal voltage-gated sodium chan-
nel SCN1A in familial hemiplegic migraine. Lancet 2005; 366: 371–7.
Diss JK, Fraser SP, Djamgoz MB. Voltage-gated Na + channels: multipli-
city of expression, plasticity, functional implications and pathophysio-
logical aspects. Eur Biophys J 2004; 33: 180–93.
Dong XW, Goregoaker S, Engler H, Zhou X, Mark L, Crona J, et al. Small
interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodo-
toxin-resistant sodium channel reverses mechanical allodynia in neuro-
pathic rats. Neuroscience 2007; 146: 812–21.
Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics
2007; 4: 145–8.
Voltage-gated sodium channels Brain 2012: 135; 2585–2612 | 2605
Dreifuss FE. Treatment of the nonconvulsive epilepsies. Epilepsia 1983;
24 (Suppl 1): S45–54.
Drizin I, Gregg RJ, Scanio MJ, Shi L, Gross MF, Atkinson RN, et al.
Discovery of potent furan piperazine sodium channel blockers
for treatment of neuropathic pain. Bioorg Med Chem 2008; 16:
6379–86.
Durham D. Management of status epilepticus. Crit Care Resusc 1999; 1:
344–53.
Ebell MH. Systemic lidocaine or mexiletine for neuropathic pain. Am Fam
Physician 2006; 74: 79.
Ekberg J, Jayamanne A, Vaughan CW, Aslan S, Thomas L, Mould J, et al.
muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron spe-
cific sodium channels and chronic pain behavior without motor def-
icits. Proc Natl Acad Sci USA 2006; 103: 17030–5.
Ernst SJ, Aguilar-Bryan L, Noebels JL. Sodium channel beta1 regulatory
subunit deficiency reduces pancreatic islet glucose-stimulated insulin
and glucagon secretion. Endocrinology 2009; 150: 1132–9.
Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvul-
sant lacosamide selectively enhances slow inactivation of voltage-
gated sodium channels. Mol Pharmacol 2008; 73: 157–69.
Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, An-
Gourfinkel I, et al. Mutations of SCN1A, encoding a neuronal
sodium channel, in two families with GEFS + 2. Nat Genet 2000; 24:
343–5.
Estacion M, Gasser A, Dib-Hajj SD, Waxman SG. A sodium channel
mutation linked to epilepsy increases ramp and persistent current of
Nav1.3 and induces hyperexcitability in hippocampal neurons. Exp
Neurol 2010; 224: 362–8.
Fang X, Djouhri L, Black JA, Dib-Hajj SD, Waxman SG, Lawson SN. The
presence and role of the tetrodotoxin-resistant sodium channel
Na(v)1.9 (NaN) in nociceptive primary afferent neurons. J Neurosci
2002; 22: 7425–33.
Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV,
Abrahamsen B, et al. SCN9A mutations in paroxysmal extreme pain
disorder: allelic variants underlie distinct channel defects and pheno-
types. Neuron 2006; 52: 767–74.
Fertleman CR, Ferrie CD, Aicardi J, Bednarek NA, Eeg-Olofsson O,
Elmslie FV, et al. Paroxysmal extreme pain disorder (previously familial
rectal pain syndrome). Neurology 2007; 69: 586–95.
Fink DJ, Wechuck J, Mata M, Glorioso JC, Goss J, Krisky D, et al. Gene
therapy for pain: results of a phase I clinical trial. Ann Neurol 2011; 70:
207–12.
Fischer J, Pschorn U, Vix JM, Peil H, Aicher B, Muller A, et al. Efficacy
and tolerability of ambroxol hydrochloride lozenges in sore
throat. Randomised, double-blind, placebo-controlled trials regarding
the local anaesthetic properties. Arzneimittelforschung 2002; 52:
256–63.
Fischer TZ, Gilmore ES, Estacion M, Eastman E, Taylor S, Melanson M,
et al. A novel Nav1.7 mutation producing carbamazepine-responsive
erythromelalgia. Ann Neurol 2009; 65: 733–41.
Fletcher EV, Kullmann DM, Schorge S. Alternative splicing modulates
inactivation of type 1 voltage-gated sodium channels by toggling
an amino acid in the first S3-S4 linker. J Biol Chem 2011; 286:
36700–8.
Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF, et al.
Voltage-gated sodium channel expression and potentiation of human
breast cancer metastasis. Clin Cancer Res 2005; 11: 5381–9.
Fraser SP, Diss JK, Lloyd LJ, Pani F, Chioni AM, George AJ, et al.
T-lymphocyte invasiveness: control by voltage-gated Na + channel ac-
tivity. FEBS Lett 2004; 569: 191–4.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL,
et al. Efficacy and tolerability of the new antiepileptic drugs II: treat-
ment of refractory epilepsy: report of the Therapeutics and Technology
Assessment Subcommittee and Quality Standards Subcommittee of the
American Academy of Neurology and the American Epilepsy Society.
Neurology 2004; 62: 1261–73.
Gaida W, Klinder K, Arndt K, Weiser T. Ambroxol, a Nav1.8-preferring
Na + channel blocker, effectively suppresses pain symptoms in animal
models of chronic, neuropathic and inflammatory pain.
Neuropharmacology 2005; 49: 1220–7.
Ganjehei L, Massumi A, Nazeri A, Razavi M. Pharmacologic manage-
ment of arrhythmias. Tex Heart Inst J 2011; 38: 344–9.
Garrido JJ, Fernandes F, Moussif A, Fache MP, Giraud P, Dargent B.
Dynamic compartmentalization of the voltage-gated sodium channels
in axons. Biol Cell 2003; 95: 437–45.
Gasser A, Ho TS, Cheng X, Chang KJ, Waxman SG, Rasband MN, et al.
An ankyrinG-binding motif is necessary and sufficient for targeting
Nav1.6 sodium channels to axon initial segments and nodes of ranvier.
J Neurosci 2012; 32: 7232–43.
Giardina EG. Procainamide: clinical pharmacology and efficacy against
ventricular arrhythmias. Ann N Y Acad Sci 1984; 432: 177–88.
Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP,
Mattice M, et al. Loss-of-function mutations in the Nav1.7 gene
underlie congenital indifference to pain in multiple human populations.
Clin Genet 2007; 71: 311–9.
Goldin AL, Barchi RL, Caldwell JH, Hofmann F, Howe JR, Hunter JC,
et al. Nomenclature of voltage-gated sodium channels. Neuron 2000;
28: 365–8.
Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine
in the treatment of postherpetic neuralgia. Clin J Pain 2000; 16:
188–92.
Grieco TM, Malhotra JD, Chen C, Isom LL, Raman IM. Open-channel
block by the cytoplasmic tail of sodium channel beta4 as a mechanism
for resurgent sodium current. Neuron 2005; 45: 233–44.
Grieco TM, Raman IM. Production of resurgent current in NaV1.6-null
Purkinje neurons by slowing sodium channel inactivation with
beta-pompilidotoxin. J Neurosci 2004; 24: 35–42.
Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O.
Lamotrigine and seizure aggravation in severe myoclonic epilepsy.
Epilepsia 1998; 39: 508–12.
Haimovich B, Schotland DL, Fieles WE, Barchi RL. Localization of sodium
channel subtypes in adult rat skeletal muscle using channel-specific
monoclonal antibodies. J Neurosci 1987; 7: 2957–66.
Hains BC, Klein JP, Saab CY, Craner MJ, Black JA, Waxman SG.
Upregulation of sodium channel Nav1.3 and functional involvement
in neuronal hyperexcitability associated with central neuropathic pain
after spinal cord injury. J Neurosci 2003; 23: 8881–92.
Hains BC, Saab CY, Klein JP, Craner MJ, Waxman SG. Altered
sodium channel expression in second-order spinal sensory neurons
contributes to pain after peripheral nerve injury. J Neurosci 2004;
24: 4832–9.
Hakim P, Brice N, Thresher R, Lawrence J, Zhang Y, Jackson AP, et al.
Scn3b knockout mice exhibit abnormal sino-atrial and cardiac conduc-
tion properties. Acta Physiol 2010; 198: 47–59.
Hakim P, Gurung IS, Pedersen TH, Thresher R, Brice N, Lawrence J, et al.
Scn3b knockout mice exhibit abnormal ventricular electrophysiological
properties. Prog Biophys Mol Biol 2008; 98: 251–66.
Harmer AR, Valentin JP, Pollard CE. On the relationship between block
of the cardiac Na channel and drug-induced prolongation of the QRS
complex. Br J Pharmacol 2011; 164: 260–73.
Hasegawa H. Utilization of zonisamide in patients with chronic pain or
epilepsy refractory to other treatments: a retrospective, open label,
uncontrolled study in a VA hospital. Curr Med Res Opin 2004; 20:
577–80.
Heblich F, Tran Van MA, Hendrich J, Watschinger K, Dolphin AC. Time
course and specificity of the pharmacological disruption of the traffick-
ing of voltage-gated calcium channels by gabapentin. Channels 2008;
2: 4–9.
Hedstrom KL, Rasband MN. Intrinsic and extrinsic determinants of ion
channel localization in neurons. J Neurochem 2006; 98: 1345–52.
Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K,
Striessnig J, et al. Pharmacological disruption of calcium channel traf-
ficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA
2008; 105: 3628–33.
Herfst LJ, Potet F, Bezzina CR, Groenewegen WA, Le MH, Hoorntje TM,
et al. Na + channel mutation leading to loss of function and non-
2606 | Brain 2012: 135; 2585–2612 N. Eijkelkamp et al.
progressive cardiac conduction defects. J Mol Cell Cardiol 2003; 35:
549–57.
Hernandez-Plata E, Ortiz CS, Marquina-Castillo B, Medina-Martinez I,
Alfaro A, Berumen J, et al. Over expression of Na(V) 1.6 channels is
associated with the invasion capacity of human cervical cancer. Int J
Cancer 2012; 130: 2013–23.
Heron SE, Crossland KM, Andermann E, Phillips HA, Hall AJ, Bleasel A,
et al. Sodium-channel defects in benign familial neonatal-infantile seiz-
ures. Lancet 2002; 360: 851–2.
Hewitt KE, Stys PK, Lesiuk HJ. The use-dependent sodium channel
blocker mexiletine is neuroprotective against global ischemic injury.
Brain Res 2001; 898: 281–7.
Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the
drug-receptor reaction. J Gen Physiol 1977; 69: 497–515.
Hiyama TY, Watanabe E, Okado H, Noda M. The subfornical organ is
the primary locus of sodium-level sensing by Na(x) sodium channels
for the control of salt-intake behavior. J Neurosci 2004; 24: 9276–81.
Hoeijmakers JG, Han C, Merkies IS, Macala LJ, Lauria G, Gerrits MM,
et al. Small nerve fibres, small hands and small feet: a new syndrome
of pain, dysautonomia and acromesomelia in a kindred with a novel
NaV1.7 mutation. Brain 2012; 135: 345–58.
Holland KD, Kearney JA, Glauser TA, Buck G, Keddache M, Blankston JR,
et al. Mutation of sodium channel SCN3A in a patient with crypto-
genic pediatric partial epilepsy. Neurosci Lett 2008a; 433: 65–70.
Holland KD, Kearney JA, Glauser TA, Buck G, Keddache M, Blankston JR,
et al. Mutation of sodium channel SCN3A in a patient with crypto-
genic pediatric partial epilepsy. Neurosci Lett 2008b; 433: 65–70.
Hollmann MW, Durieux ME. Local anesthetics and the inflammatory
response: a new therapeutic indication? Anesthesiology 2000; 93:
858–75.
Hoyt SB, London C, Gorin D, Wyvratt MJ, Fisher MH, Abbadie C, et al.
Discovery of a novel class of benzazepinone Na(v)1.7 blockers: poten-
tial treatments for neuropathic pain. Bioorg Med Chem Lett 2007; 17:
4630–4.
Hsueh CH, Chen WP, Lin JL, Tsai CT, Liu YB, Juang JM, et al. Distinct
functional defect of three novel Brugada syndrome related cardiac
sodium channel mutations. J Biomed Sci 2009; 16: 23.
Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A,
et al. A mutation in the beta 3 subunit of the cardiac sodium channel
associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009;
2: 270–8.
Huth T, Rittger A, Saftig P, Alzheimer C. beta-Site APP-cleaving
enzyme 1(BACE1)cleavescerebellar Na + channel beta4-subunit and
promotes Purkinje cell firing by slowing the decay of resurgent Na +
current. Pflugers Arch 2011; 461: 355–71.
Iqbal J, Bhat MI, Charoo BA, Syed WA, Sheikh MA, Bhat IN. Experience
with oral mexiletine in primary erythromelalgia in children. Ann Saudi
Med 2009; 29: 316–8.
Isom LL. The role of sodium channels in cell adhesion. Front Biosci 2002;
7: 12–23.
Isom LL, De Jongh KS, Patton DE, Reber BF, Offord J, Charbonneau H,
et al. Primary structure and functional expression of the beta 1 subunit
of the rat brain sodium channel. Science 1992; 256: 839–42.
Jang HS, Jung D, Kim S, Jo J, Lee J, Kim M, et al. A case of primary
erythromelalgia improved by mexiletine. Br J Dermatol 2004; 151:
708–10.
Jarecki BW, Piekarz AD, Jackson JO, Cummins TR. Human voltage-gated
sodium channel mutations that cause inherited neuronal and muscle
channelopathies increase resurgent sodium currents. J Clin Invest
2010; 120: 369–78.
Jarecki BW, Sheets PL, Jackson JO, Cummins TR. Paroxysmal extreme
pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause
moderate destabilization of fast inactivation. J Physiol 2008; 586:
4137–53.
Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, et al.
A-803467, a potent and selective Nav1.8 sodium channel blocker,
attenuates neuropathic and inflammatory pain in the rat. Proc Natl
Acad Sci USA 2007; 104: 8520–5.
Jenkins SM, Bennett V. Ankyrin-G coordinates assembly of the
spectrin-based membrane skeleton, voltage-gated sodium channels,
and L1 CAMs at Purkinje neuron initial segments. J Cell Biol 2001;
155: 739–46.
Jiang Y, Lee A, Chen J, Ruta V, Cadene M, Chait BT, et al. X-ray struc-
ture of a voltage-dependent K + channel. Nature 2003a; 423: 33–41.
Jiang Y, Ruta V, Chen J, Lee A, MacKinnon R. The principle of gating
charge movement in a voltage-dependent K + channel. Nature 2003b;
423: 42–8.
Joshi SK, Mikusa JP, Hernandez G, Baker S, Shieh CC, Neelands T, et al.
Involvement of the TTX-resistant sodium channel Nav 1.8 in inflam-
matory and neuropathic, but not post-operative, pain states. Pain
2006; 123: 75–82.
Jurkat-Rott K, Holzherr B, Fauler M, Lehmann-Horn F. Sodium channe-
lopathies of skeletal muscle result from gain or loss of function.
Pflugers Arch Eur J Physiol 2010; 460: 239–48.
Kalra AA, Elliott D. Acute migraine: current treatment and emerging
therapies. Ther Clin Risk Manag 2007; 3: 449–59.
Kalume F, Yu FH, Westenbroek RE, Scheuer T, Catterall WA. Reduced
sodium current in Purkinje neurons from Nav1.1 mutant mice: impli-
cations for ataxia in severe myoclonic epilepsy in infancy. J Neurosci
2007; 27: 11065–74.
Kaplan MR, Cho MH, Ullian EM, Isom LL, Levinson SR, Barres BA.
Differential control of clustering of the sodium channels Na(v)1.2
and Na(v)1.6 at developing CNS nodes of Ranvier. Neuron 2001;
30: 105–19.
Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium
and calcium entry protect axons from nitric oxide-mediated degener-
ation. Ann Neurol 2003; 53: 174–80.
Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al.
Lamotrigine for neuroprotection in secondary progressive multiple
sclerosis: a randomised, double-blind, placebo-controlled,
parallel-group trial. Lancet Neurol 2010; 9: 681–8.
Kapoor R, Li YG, Smith KJ. Slow sodium-dependent potential oscillations
contribute to ectopic firing in mammalian demyelinated axons. Brain
1997; 120 (Pt 4): 647–52.
Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, et al.
An international compendium of mutations in the SCN5A-encoded
cardiac sodium channel in patients referred for Brugada syndrome
genetic testing. Heart Rhythm 2010; 7: 33–46.
Kearney JA, Buchner DA, De Haan G, Adamska M, Levin SI, Furay AR,
et al. Molecular and pathological effects of a modifier gene on
deficiency of the sodium channel Scn8a (Na(v)1.6). Hum Mol Genet
2002; 11: 2765–75.
Kerr BJ, Souslova V, McMahon SB, Wood JN. A role for the
TTX-resistant sodium channel Nav 1.8 in NGF-induced hyperalgesia,
but not neuropathic pain. Neuroreport 2001; 12: 3077–80.
Khasar SG, Gold MS, Levine JD. A tetrodotoxin-resistant sodium current
mediates inflammatory pain in the rat. Neurosci Lett 1998; 256:
17–20.
Khoromi S, Patsalides A, Parada S, Salehi V, Meegan JM, Max MB.
Topiramate in chronic lumbar radicular pain. J Pain 2005; 6: 829–36.
Klionsky L, Tamir R, Holzinger B, Bi X, Talvenheimo J, Kim H, et al. A
polyclonal antibody to the prepore loop of transient receptor potential
vanilloid type 1 blocks channel activation. J Pharmacol Exp Ther 2006;
319: 192–8.
Kort ME, Drizin I, Gregg RJ, Scanio MJ, Shi L, Gross MF, et al. Discovery
and biological evaluation of 5-aryl-2-furfuramides, potent and se-
lective blockers of the Nav1.8 sodium channel with efficacy in
models of neuropathic and inflammatory pain. J Med Chem 2008;
51: 407–16.
Kudrow L, Kudrow DB, Sandweiss JH. Rapid and sustained relief of mi-
graine attacks with intranasal lidocaine: preliminary findings. Headache
1995; 35: 79–82.
Kuhnert SM, Phillips WJ, Davis MD. Lidocaine and mexiletine therapy for
erythromelalgia. Arch Dermatol 1999; 135: 1447–9.
Kuo CC, Bean BP. Na + channels must deactivate to recover from in-
activation. Neuron 1994; 12: 819–29.
Voltage-gated sodium channels Brain 2012: 135; 2585–2612 | 2607
Kyndt F, Probst V, Potet F, Demolombe S, Chevallier JC, Baro I, et al.
Novel SCN5A mutation leading either to isolated cardiac conduction
defect or Brugada syndrome in a large French family. Circulation 2001;
104: 3081–6.
Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, Hunter JC, et al. Inhibition
of neuropathic pain by decreased expression of the tetrodotoxin-
resistant sodium channel, NaV1.8. Pain 2002; 95: 143–52.
Lamas JA, Romero M, Reboreda A, Sanchez E, Ribeiro SJ. A riluzole- and
valproate-sensitive persistent sodium current contributes to the resting
membrane potential and increases the excitability of sympathetic neur-
ones. Pflugers Arch 2009; 458: 589–99.
Lampl I, Schwindt P, Crill W. Reduction of cortical pyramidal neuron
excitability by the action of phenytoin on persistent Na + current. J
Pharmacol Exp Ther 1998; 284: 228–37.
Lemaillet G, Walker B, Lambert S. Identification of a conserved
ankyrin-binding motif in the family of sodium channel alpha subunits.
J Biol Chem 2003; 278: 27333–9.
Leo S, D’Hooge R, Meert T. Exploring the role of nociceptor-specific
sodium channels in pain transmission using Nav1.8 and Nav1.9 knock-
out mice. Behav Brain Res 2010; 208: 149–57.
Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmaco-
kinetics. Seizure 2004; 13: S5–9.
Leterrier C, Brachet A, Fache MP, Dargent B. Voltage-gated sodium
channel organization in neurons: protein interactions and trafficking
pathways. Neurosci Lett 2010; 486: 92–100.
Levin SI, Khaliq ZM, Aman TK, Grieco TM, Kearney JA, Raman IM, et al.
Impaired motor function in mice with cell-specific knockout of sodium
channel Scn8a (NaV1.6) in cerebellar purkinje neurons and granule
cells. J Neurophysiol 2006; 96: 785–93.
Liao Y, Anttonen AK, Liukkonen E, Gaily E, Maljevic S, Schubert S, et al.
SCN2A mutation associated with neonatal epilepsy, late-onset episodic
ataxia, myoclonus, and pain. Neurology 2010; 75: 1454–8.
Liao YJ, Safa P, Chen YR, Sobel RA, Boyden ES, Tsien RW. Anti-Ca2 +
channel antibody attenuates Ca2 + currents and mimics cerebellar
ataxia in vivo. Proc Natl Acad Sci USA 2008; 105: 2705–10.
Lim TK, Macleod BA, Ries CR, Schwarz SK. The quaternary lidocaine
derivative, QX-314, produces long-lasting local anesthesia in animal
models in vivo. Anesthesiology 2007; 107: 305–11.
Lindia JA, Kohler MG, Martin WJ, Abbadie C. Relationship between
sodium channel NaV1.3 expression and neuropathic pain behavior in
rats. Pain 2005; 117: 145–53.
Liu H, Zhang HX, Hou HY, Lu XF, Wei JQ, Wang CG, et al. Acid solution
is a suitable medium for introducing QX-314 into nociceptors through
TRPV1 channels to produce sensory-specific analgesic effects. PLoS
One 2011; 6: e29395.
London C, Hoyt SB, Parsons WH, Williams BS, Warren VA, Tschirret-
Guth R, et al. Imidazopyridines: a novel class of hNav1.7 channel
blockers. Bioorg Med Chem Lett 2008; 18: 1696–701.
Lopez-Santiago LF, Meadows LS, Ernst SJ, Chen C, Malhotra JD,
McEwen DP, et al. Sodium channel Scn1b null mice exhibit prolonged
QT and RR intervals. J Mol Cell Cardiol 2007; 43: 636–47.
Lopez-Santiago LF, Pertin M, Morisod X, Chen C, Hong S, Wiley J, et al.
Sodium channel beta2 subunits regulate tetrodotoxin-sensitive sodium
channels in small dorsal root ganglion neurons and modulate the re-
sponse to pain. J Neurosci 2006; 26: 7984–94.
Mackenzie FE, Parker A, Parkinson NJ, Oliver PL, Brooker D, Underhill P,
et al. Analysis of the mouse mutant Cloth-ears shows a role for the
voltage-gated sodium channel Scn8a in peripheral neural hearing loss.
Genes Brain Behav 2009; 8: 699–713.
Maitre M. The gamma-hydroxybutyrate signalling system in brain: or-
ganization and functional implications. Prog Neurobiol 1997; 51:
337–61.
Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated
sodium channels as therapeutic targets in epilepsy and other neuro-
logical disorders. Lancet Neurol 2010; 9: 413–24.
Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain
2000; 87: 7–17.
Marini C, Scheffer IE, Nabbout R, Mei D, Cox K, Dibbens LM, et al.
SCN1A duplications and deletions detected in Dravet syndrome: im-
plications for molecular diagnosis. Epilepsia 2009; 50: 1670–8.
Martin MS, Tang B, Papale LA, Yu FH, Catterall WA, Escayg A. The
voltage-gated sodium channel Scn8a is a genetic modifier of severe
myoclonic epilepsy of infancy. Hum Mol Genet 2007; 16: 2892–9.
Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV,
Browne TR, et al. Comparison of carbamazepine, phenobarbital,
phenytoin, and primidone in partial and secondarily generalized
tonic-clonic seizures. N Engl J Med 1985; 313.
McGaraughty S, Chu KL, Scanio MJ, Kort ME, Faltynek CR, Jarvis MF. A
selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophe-
nyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal
neuronal activity in neuropathic rats. J Pharmacol Exp Ther 2008;
324: 1204–11.
McGowan E, Hoyt SB, Li X, Lyons KA, Abbadie C. A peripherally acting
Na(v)1.7 sodium channel blocker reverses hyperalgesia and allodynia
on rat models of inflammatory and neuropathic pain. Anesth Analg
2009; 109: 951–8.
Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, Ye B,
et al. SCN4B-encoded sodium channel beta4 subunit in congenital
long-QT syndrome. Circulation 2007; 116: 134–42.
Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and
other neurological disorders. J Clin Invest 2005; 115: 2010–7.
Meisler MH, Kearney JA, Sprunger LK, MacDonald BT, Buchner DA,
Escayg A. Mutations of voltage-gated sodium channels in movement
disorders and epilepsy. Novartis Found Symp 2002; 241: 72–81.
Meisler MH, O’Brien JE, Sharkey LM. Sodium channel gene family: epi-
lepsy mutations, gene interactions and modifier effects. J Physiol 2010;
588: 1841–8.
Meisler MH, Plummer NW, Burgess DL, Buchner DA, Sprunger LK. Allelic
mutations of the sodium channel SCN8A reveal multiple cellular and
physiological functions. Genetica 2004; 122: 37–45.
Middleton RE, Warren VA, Kraus RL, Hwang JC, Liu CJ, Dai G, et al.
Two tarantula peptides inhibit activation of multiple sodium channels.
Biochemistry 2002; 41: 14734–47.
Minett MS, Nassar MA, Clark AK, Passmore G, Dickenson AH, Wang F,
et al. Distinct Nav1.7-dependent pain sensations require different sets
of sensory and sympathetic neurons. Nat Commun 2012; 3: 791.
Misra SN, Kahlig KM, George AL Jr. Impaired NaV1.2 function and
reduced cell surface expression in benign familial neonatal-infantile
seizures. Epilepsia 2008; 49: 1535–45.
Mohammadi B, Jurkat-Rott K, Alekov A, Dengler R, Bufler J, Lehmann-
Horn F. Preferred mexiletine block of human sodium channels with
IVS4 mutations and its pH-dependence. Pharmacogenet Genomics
2005; 15: 235–44.
Mohler PJ, Rivolta I, Napolitano C, Lemaillet G, Lambert S, Priori SG,
et al. Nav1.5 E1053K mutation causing Brugada syndrome blocks
binding to ankyrin-G and expression of Nav1.5 on the surface of
cardiomyocytes. Proc Natl Acad Sci USA 2004; 101: 17533–8.
Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al.
Malformation risks of antiepileptic drugs in pregnancy: a prospective
study from the UK Epilepsy and Pregnancy Register. J Neurol
Neurosurg Psychiatry 2006; 77: 193–8.
Muth-Selbach U, Hermanns H, Stegmann JU, Kollosche K,
Freynhagen R, Bauer I, et al. Antinociceptive effects of systemic lido-
caine: involvement of the spinal glycinergic system. Eur J Pharmacol
2009; 613: 68–73.
Nalamachu S, Crockett RS, Mathur D. Lidocaine patch 5 for carpal
tunnel syndrome: how it compares with injections: a pilot study. J
Fam Pract 2006; 55: 209–14.
Nassar MA, Baker MD, Levato A, Ingram R, Mallucci G, McMahon SB,
et al. Nerve injury induces robust allodynia and ectopic discharges in
Nav1.3 null mutant mice. Mol Pain 2006; 2: 33.
Nassar MA, Levato A, Stirling LC, Wood JN. Neuropathic pain de-
velops normally in mice lacking both Nav1.7 and Nav1.8. Mol Pain
2005; 1: 24.
2608 | Brain 2012: 135; 2585–2612 N. Eijkelkamp et al.
Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA,
Dickenson AH, et al. Nociceptor-specific gene deletion reveals a
major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc
Natl Acad Sci USA 2004; 101: 12706–11.
Nattel S. Comparative mechanisms of action of antiarrhythmic drugs. Am
J Cardiol 1993; 72: 13F–7F.
Naylor J, Milligan CJ, Zeng F, Jones C, Beech DJ. Production of a specific
extracellular inhibitor of TRPM3 channels. Br J Pharmacol 2008; 155:
567–73.
Nuyens D, Stengl M, Dugarmaa S, Rossenbacker T, Compernolle V,
Rudy Y, et al. Abrupt rate accelerations or premature beats cause
life-threatening arrhythmias in mice with long-QT3 syndrome. Nat
Med 2001; 7: 1021–7.
O’Brien JE, Sharkey LM, Vallianatos CN, Han C, Blossom JC, Yu T, et al.
Interaction of voltage-gated sodium channel Nav1.6 (SCN8A) with
microtubule associated protein Map1b. J Biol Chem 2012; 287:
18459–66.
O’Malley HA, Shreiner AB, Chen GH, Huffnagle GB, Isom LL. Loss of
Na + channel beta2 subunits is neuroprotective in a mouse model of
multiple sclerosis. Mol Cell Neurosci 2009; 40: 143–55.
O’Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S, et al.
Exome sequencing in sporadic autism spectrum disorders identifies
severe de novo mutations. Nat Genet 2011; 43: 585–9.
O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al.
Sporadic autism exomes reveal a highly interconnected protein net-
work of de novo mutations. Nature 2012; 485: 246–50.
Okuse K, Malik-Hall M, Baker MD, Poon WY, Kong H, Chao MV, et al.
Annexin II light chain regulates sensory neuron-specific sodium chan-
nel expression. Nature 2002; 417: 653–6.
Onkal R, Djamgoz MBA. Molecular pharmacology of voltage-gated
sodium channel expression in metastatic disease: clinical potential of
neonatal Nav1.5 in breast cancer. Eur J Pharmacol 2009; 625: 206–19.
Ostman JA, Nassar MA, Wood JN, Baker MD. GTP up-regulated persist-
ent Na + current and enhanced nociceptor excitability require NaV1.9.
J Physiol 2008; 586: 1077–87.
Ou S-W, Kameyama A, Hao L-Y, Horiuchi M, Minobe E, Wang W-Y,
et al. Tetrodotoxin-resistant Na + channels in human neuroblastoma
cells are encoded by new variants of Nav1.5/SCN5A. Eur J Neurosci
2005; 22: 793–801.
Oyama F, Miyazaki H, Sakamoto N, Becquet C, Machida Y, Kaneko K,
et al. Sodium channel beta4 subunit: down-regulation and possible
involvement in neuritic degeneration in Huntington’s disease trans-
genic mice. J Neurochem 2006; 98: 518–29.
Padilla F, Couble ML, Coste B, Maingret F, Clerc N, Crest M, et al.
Expression and localization of the Nav1.9 sodium channel in enteric
neurons and in trigeminal sensory endings: implication for intestinal
reflex function and orofacial pain. Mol Cell Neurosci 2007; 35:
138–52.
Papadatos GA, Wallerstein PM, Head CE, Ratcliff R, Brady PA,
Benndorf K, et al. Slowed conduction and ventricular tachycardia
after targeted disruption of the cardiac sodium channel gene Scn5a.
Proc Natl Acad Sci USA 2002; 99: 6210–5.
Papale LA, Paul KN, Sawyer NT, Manns JR, Tufik S, Escayg A.
Dysfunction of the Scn8a voltage-gated sodium channel alters sleep
architecture, reduces diurnal corticosterone levels, and enhances spatial
memory. J Biol Chem 2010; 285: 16553–61.
Patino GA, Brackenbury WJ, Bao Y, Lopez-Santiago LF, O’Malley HA,
Chen C, et al. Voltage-gated Na + channel beta1B: a secreted cell
adhesion molecule involved in human epilepsy. J Neurosci 2011; 31:
14577–91.
Patino GA, Claes LR, Lopez-Santiago LF, Slat EA, Dondeti RS, Chen C,
et al. A functional null mutation of SCN1B in a patient with Dravet
syndrome. J Neurosci 2009; 29: 10764–78.
Patino GA, Isom LL. Electrophysiology and beyond: multiple roles of
Na + channel beta subunits in development and disease. Neurosci
Lett 2010; 486: 53–9.
Patlak JB, Ortiz M. Two modes of gating during late Na + channel cur-
rents in frog sartorius muscle. J Gen Physiol 1986; 87: 305–26.
Payandeh J, Gamal El-Din TM, Scheuer T, Zheng N, Catterall WA.
Crystal structure of a voltage-gated sodium channel in two potentially
inactivated states. Nature 2012; 486: 135–9.
Payandeh J, Scheuer T, Zheng N, Catterall WA. The crystal structure of a
voltage-gated sodium channel. Nature 2011; 475: 353–8.
Pertin M, Ji RR, Berta T, Powell AJ, Karchewski L, Tate SN, et al.
Upregulation of the voltage-gated sodium channel beta2 subunit
in neuropathic pain models: characterization of expression in injured
and non-injured primary sensory neurons. J Neurosci 2005; 25:
10970–80.
Perucca E, Tomson T. The pharmacological treatment of epilepsy in
adults. Lancet Neurol 2011; 10: 446–56.
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G.
Riluzole in the treatment of mood and anxiety disorders. CNS drugs
2008; 22: 761–86.
Planells-Cases R, Caprini M, Zhang J, Rockenstein EM, Rivera RR,
Murre C, et al. Neuronal death and perinatal lethality in voltage-gated
sodium channel alpha(II)-deficient mice. Biophys J 2000; 78: 2878–91.
Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of
h-channels reduces the excitability of pyramidal neuron dendrites.
Nat Neurosci 2002; 5: 767–74.
Poon WY, Malik-Hall M, Wood JN, Okuse K. Identification of
binding domains in the sodium channel Na(V)1.8 intracellular
N-terminal region and annexin II light chain p11. FEBS Lett 2004;
558: 114–8.
Priest BT, Blumenthal KM, Smith JJ, Warren VA, Smith MM. ProTx-I and
ProTx-II: gating modifiers of voltage-gated sodium channels. Toxicon
2007; 49: 194–201.
Priest BT, Garcia ML, Middleton RE, Brochu RM, Clark S, Dai G, et al. A
disubstituted succinamide is a potent sodium channel blocker with ef-
ficacy in a rat pain model. Biochemistry 2004; 43: 9866–76.
Priest BT, Murphy BA, Lindia JA, Diaz C, Abbadie C, Ritter AM, et al.
Contribution of the tetrodotoxin-resistant voltage-gated sodium chan-
nel NaV1.9 to sensory transmission and nociceptive behavior. Proc
Natl Acad Sci USA 2005; 102: 9382–7.
Ptacek LJ, George AL Jr, Griggs RC, Tawil R, Kallen RG, Barchi RL, et al.
Identification of a mutation in the gene causing hyperkalemic periodic
paralysis. Cell 1991; 67: 1021–7.
Ragsdale DS. How do mutant Nav1.1 sodium channels cause epilepsy?
Brain Res Rev 2008; 58: 149–59.
Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Molecular determin-
ants of state-dependent block of Na + channels by local anesthetics.
Science 1994; 265: 1724–8.
Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Common molecular
determinants of local anesthetic, antiarrhythmic, and anticonvulsant
block of voltage-gated Na + channels. Proc Natl Acad Sci USA
1996; 93: 9270–5.
Rajakulendran S, Tan SV, Matthews E, Tomlinson SE, Labrum R, Sud R,
et al. A patient with episodic ataxia and paramyotonia congenita due
to mutations in KCNA1 and SCN4A. Neurology 2009; 73: 993–5.
Raman IM, Bean BP. Resurgent sodium current and action potential
formation in dissociated cerebellar Purkinje neurons. J Neurosci
1997; 17: 4517–26.
Raman IM, Sprunger LK, Meisler MH, Bean BP. Altered subthreshold
sodium currents and disrupted firing patterns in Purkinje neurons of
Scn8a mutant mice. Neuron 1997; 19: 881–91.
Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful
diabetic peripheral neuropathy: a phase 2 double-blind
placebo-controlled study. Clin J Pain 2007; 23: 150–58.
Renganathan M, Cummins TR, Waxman SG. Contribution of Na(v)1.8
sodium channels to action potential electrogenesis in DRG neurons. J
Neurophysiol 2001; 86: 629–40.
Rivera-Acevedo RE, Pless SA, Ahern CA, Schwarz SK. The quaternary
lidocaine derivative, QX-314, exerts biphasic effects on transient re-
ceptor potential vanilloid subtype 1 channels in vitro. Anesthesiology
2011; 114: 1425–34.
Roberson DP, Binshtok AM, Blasl F, Bean BP, Woolf CJ. Targeting of
sodium channel blockers into nociceptors to produce long-duration
Voltage-gated sodium channels Brain 2012: 135; 2585–2612 | 2609
analgesia: a systematic study and review. Br J Pharmacol 2011; 164:
48–58.
Robinson LR, Czerniecki JM, Ehde DM, Edwards WT, Judish DA,
Goldberg ML, et al. Trial of amitriptyline for relief of pain in amputees:
results of a randomized controlled study. Arch Phys Med Rehabil
2004; 85: 1–6.
Rogart RB, Cribbs LL, Muglia LK, Kephart DD, Kaiser MW. Molecular
cloning of a putative tetrodotoxin-resistant rat heart Na + channel
isoform. Proc Natl Acad Sci USA 1989; 86: 8170–4.
Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs
for the treatment of nonepileptic conditions. Nat Med 2004; 10:
685–92.
Roselli F, Livrea P, Jirillo E. Voltage-gated sodium channel blockers as
immunomodulators. Recent Pat CNS Drug Discov 2006; 1: 83–91.
Rosker C, Lohberger B, Hofer D, Steinecker B, Quasthoff S,
Schreibmayer W. The TTX metabolite 4,9-anhydro-TTX is a highly
specific blocker of the Na(v1.6) voltage-dependent sodium channel.
Am J Physiol Cell Physiol 2007; 293: C783–9.
Ruan Y, Denegri M, Liu N, Bachetti T, Seregni M, Morotti S, et al.
Trafficking defects and gating abnormalities of a novel SCN5A muta-
tion question gene-specific therapy in long QT syndrome type 3. Circ
Res 2010; 106: 1374–83.
Ruetsch YA, Boni T, Borgeat A. From cocaine to ropivacaine: the history
of local anesthetic drugs. Curr Top Med Chem 2001; 1: 175–82.
Rugiero F, Mistry M, Sage D, Black JA, Waxman SG, Crest M, et al.
Selective expression of a persistent tetrodotoxin-resistant Na + current
and NaV1.9 subunit in myenteric sensory neurons. J Neurosci 2003;
23: 2715–25.
Rusconi R, Scalmani P, Cassulini RR, Giunti G, Gambardella A,
Franceschetti S, et al. Modulatory proteins can rescue a trafficking
defective epileptogenic Nav1.1 Na + channel mutant. J Neurosci
2007; 27: 11037–46.
Saenen JB, Vrints CJ. Molecular aspects of the congenital and acquired
Long QT Syndrome: clinical implications. J Mol Cell Cardiol 2008; 44:
633–46.
Saleh S, Yeung SY, Prestwich S, Pucovsky V, Greenwood I.
Electrophysiological and molecular identification of voltage-gated
sodium channels in murine vascular myocytes. J Physiol 2005; 568:
155–69.
Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ,
Willsey AJ, et al. De novo mutations revealed by whole-exome
sequencing are strongly associated with autism. Nature 2012; 485:
237–41.
Scheffer IE, Harkin LA, Grinton BE, Dibbens LM, Turner SJ, Zielinski MA,
et al. Temporal lobe epilepsy and GEFS + phenotypes associated with
SCN1B mutations. Brain 2007; 130: 100–9.
Schiavon E, Sacco T, Cassulini RR, Gurrola G, Tempia F, Possani LD,
et al. Resurgent current and voltage sensor trapping enhanced activa-
tion by a beta-scorpion toxin solely in Nav1.6 channel. Significance in
mice Purkinje neurons. J Biol Chem 2006; 281: 20326–37.
Schmalhofer WA, Calhoun J, Burrows R, Bailey T, Kohler MG,
Weinglass AB, et al. ProTx-II, a selective inhibitor of NaV1.7 sodium
channels, blocks action potential propagation in nociceptors. Mol
Pharmacol 2008a; 74: 1476–84.
Schmalhofer WA, Calhoun J, Burrows R, Bailey T, Kohler MG,
Weinglass AB, et al. ProTx-II, a selective inhibitor of NaV1.7 sodium
channels, blocks action potential propagation in nociceptors. Mol
Pharmacol 2008b; 74: 1476–84.
Schwarz JR, Grigat G. Phenytoin and carbamazepine: potential- and
frequency-dependent block of Na currents in mammalian myelinated
nerve fibers. Epilepsia 1989; 30: 286–94.
Schwarz SK, Cheung HM, Ries CR, Lee SM, Wang JT, Macleod BA.
Lumbar intrathecal administration of the quaternary lidocaine deriva-
tive, QX-314, produces irritation and death in mice. Anesthesiology
2010; 113: 438–44.
Schwindt PC, Crill WE. Amplification of synaptic current by persistent
sodium conductance in apical dendrite of neocortical neurons. J
Neurophysiol 1995; 74: 2220–4.
Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical thera-
peutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 2008;
14: 120–42.
Shao D, Okuse K, Djamgoz MB. Protein-protein interactions involving
voltage-gated sodium channels: Post-translational regulation, intracel-
lular trafficking and functional expression. Int J Biochem Cell Biol 2009;
41: 1471–81.
Shao PP, Ok D, Fisher MH, Garcia ML, Kaczorowski GJ, Li C, et al.
Novel cyclopentane dicarboxamide sodium channel blockers as a po-
tential treatment for chronic pain. Bioorg Med Chem Lett 2005; 15:
1901–7.
Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory
neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acet-
ylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carba-
mazepine. J Pharmacol Exp Ther 2008; 326: 89–99.
Sheets PL, Jackson JO, Waxman SG, Dib-Hajj SD, Cummins TR. A
Nav1.7 channel mutation associated with hereditary erythromelalgia
contributes to neuronal hyperexcitability and displays reduced lido-
caine sensitivity. J Physiol 2007; 581: 1019–31.
Sijben AE, Sithinamsuwan P, Radhakrishnan A, Badawy RA, Dibbens L,
Mazarib A, et al. Does a SCN1A gene mutation confer earlier age of
onset of febrile seizures in GEFS + ? Epilepsia 2009; 50: 953–6.
Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B.
Results of a nationwide Veterans Administration Cooperative Study
comparing the efficacy and toxicity of carbamazepine, phenobarbital,
phenytoin, and primidone. Epilepsia 1987; 28: 50–8.
Smith KJ. Sodium channels and multiple sclerosis: roles in symptom pro-
duction, damage and therapy. Brain Pathol 2007; 17: 230–42.
Sokolov S, Scheuer T, Catterall WA. Gating pore current in an inherited
ion channelopathy. Nature 2007; 446: 76–8.
Sokolov S, Scheuer T, Catterall WA. Ion permeation and block of the
gating pore in the voltage sensor of NaV1.4 channels with hypokal-
emic periodic paralysis mutations. J Gen Physiol 2010; 136: 225–36.
Song JH, Ham SS, Shin YK, Lee CS. Amitriptyline modulation of Na( + )
channels in rat dorsal root ganglion neurons. Eur J Pharmacol 2000;
401: 297–305.
Spampanato J, Escayg A, Meisler MH, Goldin AL. Functional effects of
two voltage-gated sodium channel mutations that cause generalized
epilepsy with febrile seizures plus type 2. J Neurosci 2001; 21:
7481–90.
Starmer CF, Hollett MD. Mechanisms of apparent affinity variation of
guarded receptors. J Theor Biol 1985; 115: 337–49.
Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits
Ca2 + currents in cortical neurons: functional implications. Eur J
Pharmacol 1996; 307: 113–6.
Stevens EB, Cox PJ, Shah BS, Dixon AK, Richardson PJ, Pinnock RD,
et al. Tissue distribution and functional expression of the human
voltage-gated sodium channel beta3 subunit. Pflugers Arch 2001;
441: 481–8.
Stohr T, Krause E, Selve N. Lacosamide displays potent antinociceptive
effects in animal models for inflammatory pain. Eur J Pain 2006; 10:
241–9.
Stuhmer W, Conti F, Suzuki H, Wang XD, Noda M, Yahagi N, et al.
Structural parts involved in activation and inactivation of the sodium
channel. Nature 1989; 339: 597–603.
Stummann TC, Salvati P, Fariello RG, Faravelli L. The anti-nociceptive
agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-
sensitive Na + currents in dorsal root ganglion neurons. Eur J
Pharmacol 2005; 510: 197–208.
Stys PK. White matter injury mechanisms. Curr Mol Med 2004; 4:
113–30.
Sugawara T, Tsurubuchi Y, Agarwala KL, Ito M, Fukuma G, Mazaki-
Miyazaki E, et al. A missense mutation of the Na + channel alpha II
subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures
causes channel dysfunction. Proc Natl Acad Sci USA 2001; 98:
6384–9.
Sun GC, Werkman TR, Battefeld A, Clare JJ, Wadman WJ.
Carbamazepine and topiramate modulation of transient and persistent
2610 | Brain 2012: 135; 2585–2612 N. Eijkelkamp et al.
sodium currents studied in HEK293 cells expressing the Na(v)1.3
alpha-subunit. Epilepsia 2007; 48: 774–82.
Tan BH, Pundi KN, Van Norstrand DW, Valdivia CR, Tester DJ,
Medeiros-Domingo A, et al. Sudden infant death syndrome-associated
mutations in the sodium channel beta subunits. Heart Rhythm 2010;
7: 771–8.
Taverna S, Mantegazza M, Franceschetti S, Avanzini G. Valproate select-
ively reduces the persistent fraction of Na + current in neocortical
neurons. Epilepsy Res 1998; 32: 304–8.
Theile JW, Jarecki BW, Piekarz AD, Cummins TR. Nav1.7 mutations
associated with paroxysmal extreme pain disorder, but not erythrome-
lalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents.
J Physiol 2011; 589: 597–608.
Toledo-Aral JJ, Moss BL, He ZJ, Koszowski AG, Whisenand T,
Levinson SR, et al. Identification of PN1, a predominant
voltage-dependent sodium channel expressed principally in peripheral
neurons. Proc Natl Acad Sci USA 1997; 94: 1527–32.
Trudeau MM, Dalton JC, Day JW, Ranum LP, Meisler MH.
Heterozygosity for a protein truncation mutation of sodium channel
SCN8A in a patient with cerebellar atrophy, ataxia, and mental retard-
ation. J Med Genet 2006; 43: 527–30.
Uebachs M, Opitz T, Royeck M, Dickhof G, Horstmann MT, Isom LL,
et al. Efficacy loss of the anticonvulsant carbamazepine in mice lacking
sodium channel beta subunits via paradoxical effects on persistent
sodium currents. J Neurosci 2010; 30: 8489–501.
Vahedi K, Depienne C, Le FD, Riant F, Chaine P, Trouillard O, et al.
Elicited repetitive daily blindness: a new phenotype associated with
hemiplegic migraine and SCN1A mutations. Neurology 2009; 72:
1178–83.
Valdivia CR, Ackerman MJ, Tester DJ, Wada T, McCormack J, Ye B, et al. A
novel SCN5A arrhythmia mutation, M1766L, with expression defect res-
cued by mexiletine. Cardiovasc Res 2002; 55: 279–89.
Valdivia CR, Medeiros-Domingo A, Ye B, Shen WK, Algiers TJ,
Ackerman MJ, et al. Loss-of-function mutation of the SCN3B-encoded
sodium channel {beta}3 subunit associated with a case of idiopathic
ventricular fibrillation. Cardiovasc Res 2010; 86: 392–400.
Valdivia CR, Tester DJ, Rok BA, Porter C-BJ, Munger TM, Jahangir A,
et al. A trafficking defective, Brugada syndrome-causing SCN5A mu-
tation rescued by drugs. Cardiovasc Res 2004; 62: 53–62.
Vassilev P, Scheuer T, Catterall WA. Inhibition of inactivation of single
sodium channels by a site-directed antibody. Proc Natl Acad Sci USA
1989; 86: 8147–51.
Vassilev PM, Scheuer T, Catterall WA. Identification of an intracellular
peptide segment involved in sodium channel inactivation. Science
1988; 241: 1658–61.
Veeramah KR, O’Brien JE, Meisler MH, Cheng X, Dib-Hajj SD,
Waxman SG, et al. De novo pathogenic SCN8A mutation identified
by whole-genome sequencing of a family quartet affected by infantile
epileptic encephalopathy and SUDEP. Am J Hum Genet 2012; 90:
502–10.
Veneroni O, Maj R, Calabresi M, Faravelli L, Fariello RG, Salvati P.
Anti-allodynic effect of NW-1029, a novel Na( + ) channel blocker, in
experimental animal models of inflammatory and neuropathic pain.
Pain 2003; 102: 17–25.
Volkers L, Kahlig KM, Verbeek NE, Das JH, van Kempen MJ, Stroink H,
et al. Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus
or Dravet syndrome. Eur J Neurosci 2011; 34: 1268–75.
von Gunten CF, Eappen S, Cleary JF, Taylor SGt, Moots P, Regevik N,
et al. Flecainide for the treatment of chronic neuropathic pain: a Phase
II trial. Palliat Med 2007; 21: 667–72.
Walker MJ. Antiarrhythmic drug research. Br J Pharmacol 2006; 147:
222–31.
Wang P, Yang Q, Wu X, Yang Y, Shi L, Wang C, et al. Functional
dominant-negative mutation of sodium channel subunit gene SCN3B
associated with atrial fibrillation in a Chinese GeneID population.
Biochem Biophys Res Commun 2010a; 398: 98–104.
Wang Y, Brittain JM, Jarecki BW, Park KD, Wilson SM, Wang B, et al. In
silico docking and electrophysiological characterization of lacosamide
binding sites on collapsin response mediator protein-2 identifies a
pocket important in modulating sodium channel slow inactivation. J
Biol Chem 2010b; 285: 25296–307.
Wang Y, Khanna R. Voltage-gated calcium channels are not affected by
the novel anti-epileptic drug lacosamide. Transl Neurosci 2011; 2:
13–22.
Wang Z, Fermini B, Nattel S. Mechanism of flecainide’s rate-dependent
actions on action potential duration in canine atrial tissue. J Pharmacol
Exp Ther 1993; 267: 575–81.
Watanabe E, Fujikawa A, Matsunaga H, Yasoshima Y, Sako N,
Yamamoto T, et al. Nav2/NaG channel is involved in control of
salt-intake behavior in the CNS. J Neurosci 2000; 20: 7743–51.
Watanabe H, Darbar D, Kaiser DW, Jiramongkolchai K, Chopra S,
Donahue BS, et al. Mutations in sodium channel beta1- and
beta2-subunits associated with atrial fibrillation. Circ Arrhythm
Electrophysiol 2009; 2: 268–75.
Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR,
Schott JJ, et al. Sodium channel beta1 subunit mutations associated
with Brugada syndrome and cardiac conduction disease in humans. J
Clin Invest 2008; 118: 2260–8.
Waxman SG, Black JA, Ransom BR, Stys PK. Anoxic injury of rat optic
nerve: ultrastructural evidence for coupling between Na + influx and
Ca(2 + )-mediated injury in myelinated CNS axons. Brain Res 1994a;
644: 197–204.
Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA
is expressed in embryonic but not adult spinal sensory neurons,
and is reexpressed following axotomy. J Neurophysiol 1994b; 72:
466–70.
Weiser T, Wilson N. Inhibition of tetrodotoxin (TTX)-resistant and
TTX-sensitive neuronal Na( + ) channels by the secretolytic ambroxol.
Mol Pharmacol 2002; 62: 433–8.
Weiss J, Pyrski M, Jacobi E, Bufe B, Willnecker V, Schick B, et al.
Loss-of-function mutations in sodium channel Nav1.7 cause anosmia.
Nature 2011; 472: 186–90.
Weiss LA, Escayg A, Kearney JA, Trudeau M, MacDonald BT, Mori M,
et al. Sodium channels SCN1A, SCN2A and SCN3A in familial autism.
Mol Psychiatry 2003; 8: 186–94.
Weiss S, Benoist D, White E, Teng W, Saint DA. Riluzole protects against
cardiac ischaemia and reperfusion damage via block of the persistent
sodium current. Br J Pharmacol 2010; 160: 1072–82.
West JW, Patton DE, Scheuer T, Wang Y, Goldin AL, Catterall WA. A
cluster of hydrophobic amino acid residues required for fast Na( + )-
channel inactivation. Proc Natl Acad Sci USA 1992; 89: 10910–4.
Westenbroek RE, Merrick DK, Catterall WA. Differential subcellular lo-
calization of the RI and RII Na + channel subtypes in central neurons.
Neuron 1989; 3: 695–704.
Westenbroek RE, Noebels JL, Catterall WA. Elevated expression of type
II Na + channels in hypomyelinated axons of shiverer mouse brain. J
Neurosci 1992; 12: 2259–67.
Whitaker WR, Faull RL, Waldvogel HJ, Plumpton CJ, Emson PC, Clare JJ.
Comparative distribution of voltage-gated sodium channel proteins in
human brain. Brain Res Mol Brain Res 2001; 88: 37–53.
Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute
and chronic pain in adults. Cochrane Database Syst Rev 2011:
CD005451.
Williams BS, Felix JP, Priest BT, Brochu RM, Dai K, Hoyt SB, et al.
Characterization of a new class of potent inhibitors of the
voltage-gated sodium channel Nav1.7. Biochemistry 2007; 46:
4693–703.
Wilson MJ, Zhang MM, Azam L, Olivera BM, Bulaj G, Yoshikami D.
NaVbeta subunits modulate the inhibition of NaV1.8 by the analgesic
gating modifier muO-conotoxin MrVIB. J Pharmacol Exp Ther 2011;
338: 687–93.
Wimmer VC, Reid CA, Mitchell S, Richards KL, Scaf BB, Leaw BT, et al.
Axon initial segment dysfunction in a mouse model of genetic epilepsy
with febrile seizures plus. J Clin Invest 2010; 120: 2661–71.
Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, et al.
beta Subunits of voltage-gated sodium channels are novel substrates
Voltage-gated sodium channels Brain 2012: 135; 2585–2612 | 2611
of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and
gamma-secretase. J Biol Chem 2005; 280: 23009–17.
Wood JN, Boorman JP, Okuse K, Baker MD. Voltage-gated sodium
channels and pain pathways. J Neurobiol 2004; 61: 55–71.
Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, et al. Mutations in SCN9A,
encoding a sodium channel alpha subunit, in patients with primary
erythermalgia. J Med Genet 2004; 41: 171–4.
Yarbrough TL, Lu T, Lee HC, Shibata EF. Localization of cardiac sodium
channels in caveolin-rich membrane domains: regulation of sodium
current amplitude. Circ Res 2002; 90: 443–9.
Yarov-Yarovoy V, DeCaen PG, Westenbroek RE, Pan CY, Scheuer T,
Baker D, et al. Structural basis for gating charge movement in the
voltage sensor of a sodium channel. Proc Natl Acad Sci USA 2012;
109: E93–102.
Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F,
Burton KA, et al. Reduced sodium current in GABAergic interneurons
in a mouse model of severe myoclonic epilepsy in infancy. Nat
Neurosci 2006; 9: 1142–9.
Yu FH, Westenbroek RE, Silos-Santiago I, McCormick KA, Lawson D,
Ge P, et al. Sodium channel beta4, a new disulfide-linked auxiliary
subunit with similarity to beta2. J Neurosci 2003; 23: 7577–85.
Zhao J, O’Leary ME, Chahine M. Regulation of Na(v)1.6 and Na(v)1.8
peripheral nerve Na( + ) channels by auxiliary beta-subunits. J
Neurophysiol 2011; 106: 608–19.
Zimmer T, Surber R. SCN5A channelopathies–an update on mutations
and mechanisms. Prog Biophys Mol Biol 2008; 98: 120–36.
Zimmermann K, Leffler A, Babes A, Cendan CM, Carr RW, Kobayashi J,
et al. Sensory neuron sodium channel Nav1.8 is essential for pain at
low temperatures. Nature 2007; 447: 855–8.
Zona C, Tancredi V, Longone P, D’Arcangelo G, D’Antuono M,
Manfredi M, et al. Neocortical potassium currents are enhanced by
the antiepileptic drug lamotrigine. Epilepsia 2002; 43: 685–90.
2612 | Brain 2012: 135; 2585–2612 N. Eijkelkamp et al.
